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INTRODUCTION 
±¾¢Ã¾¡ì ¸¡ìÌ ÁÈ¢Å¢É÷ì¸¢ø¨Ä 
«¾¢Ã ÅÕÅ§¾¡÷ §¿¡ö 
-¾¢ÕÅûÙÅ÷. 
In South India, the Siddha system flourished earlier than the other systems. And 
also it is one of the oldest systems in India. The term ‘Siddha’ means Achievement and 
the Siddhar were saintly figures who have contributed to the development of this medical 
system. 
Siddhar is a Tamil word that is derived from its root Chiti. This means Perfection 
in life Or Heavenly bliss. It generally refers to eight kinds of paranormal powers 
(Ashtama chittigal) attainable by man, that persons are known as Siddhar. Every 
prominent temple in Tamil Nadu is attributed to those great Siddhars. 
 
±ñ½ Å¢Õ ¿¡ý¸¢§ÉüÈ º¼õ ºÃ½ÇÅ¢ø 
ÁñÏ ÖÕÅ¡¸¢ Å¡ÛÄÅô- ÀñÏÅ¢¾ 
§Á÷Å¡Ôó§¾Ô ¦ÁÆ¢ÄôÒó¾¡ý ÜÊî 
º¡ü×üÈ ¦¾ý§È ¿£ º¡üÚ. 
-¸ñÏº¡Á¢Âõ 
Siddhars knowledge in Iatro-chemistry, minerals, metals and plants were 
awesome. The process like oxidation of mercury, minerals, metals and the preparation of 
herbal medicines which cure the diseases and rejuvenate the entire human system. 
According to Siddha science to prevent the ageing process, they discovered and 
used various kinds of medicine faculties like Muppu, Kaya kalpam, Yoga and also 
Internal medicines. 
 
3 
   
“§ÀÚ þÇ¨Á þýÀõ À¢½¢ ãôÒ º¡ì¸¡Î ¬Úí¸ÕÅ¢Ä¨ÁôÒ” 
 
Preventing the ageing means to prevent the body from the various degenerative 
diseases occurring in old age. Siddha medicine places a major role in maintaining health 
of the elderly people. This medicine has potential to emerge a mainstream in health care 
delivery system of the geriatric community. 
Geriatric is a branch of medicine which emerges in the last two decades as a 
separate entity towards the health care of the elderly is called as ‘Moopu Iyal’ in Siddha 
medicine. 
The term geriatric derived from Greek. ‘Geron’ means old man, ‘Iatrica’ means 
the treatment of disease. The problems of geriatrics include altered endocrine functions, 
decreased functions of nervous system, tissues, and organs. Those problems lead the 
processing of ageing. 
In elderly males, they got so many degenerative problems. The major encountered 
problem is difficulty in voiding urine. Usually men above 60 years are affected due to the 
enlargement of prostate gland. 
The enlargement of the central part of the prostate narrows the calibra of the 
urethra passing through its middle and obstruction occurs that leads to stagnant 
micturation. Sometimes the enlargement predict as a malignant tumor. This is literally 
called as benign prostatic hyperplasia (BPH). 
The incidence of BPH increases according to the age. It is estimated that 65% of 
men at the age of 60 were suffering from BPH. The prevalence of disease is 8% in the 
age of 31 – 40 years, 40 – 50% in 50 – 60 years and 80% in above 80 years. The 
symptoms includes, delayed emerging of urine, dysuria, increased frequency of urine, 
urgency, urinary incontinence, nocturia and drippling of urine and lower abdominal pain 
at advanced stage. 
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The complications of the diseases are very threatful to life. Those are recurrent 
urinary infection, which leads to cystitis and rarely kidney failure. Severe pain in lower 
abdominal area, rectal obstruction, Prostitis, Urithritis are common. 
In Siddha disease classification of this symptoms are correlated to “UKKARA 
SOOLAI” which is one of the 15 types of Soolai Noi. 
In modern treatment UKKARA SOOLAI (BPH) is curable by surgery only. I 
prefer to select this topic for my dissertation to reduce the symptoms by a metallic 
Sasthric preparation of “VELVANGA PARPAM”.  
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AIM AND OBJECTIVES 
AIM: 
        The aim of the study is to conduct a clinical trial on Ukkara Soolai (Benign 
Prostate Hyperplasia) patients with a combination of siddha drug Velvanga Parpam 
and to improve the happiness of geriatric people. 
OBJECTIVES OF THE STUDY: 
 To review, the siddha literary evidences dealing with etiology, classification signs 
and symptoms, diagnosis, diets, prognosis of Ukkara Soolai in siddha system of 
medicine. 
 
 To identify the clinical symptoms which resemble the modern clinical presentation 
with description of Ukkara Soolai is related with benign prostate hyperplasia. 
 
 
 To gather an idea on the incidence of Ukkara Soolai with regard to age, severity   
of signs and symptoms, diets, habits and other old age diseases. 
 
 To access the role of well known siddha drugs to control all the symptoms and 
sign of Ukkara Soolai. 
 
 To systematically record the sign and symptom and the test results of full 
evaluation. 
 
 To assess the role of diagnosis tools of siddha system in the follow up as prognosis 
in clinical Ukkara Soolai. 
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 To study the  
• Acute and sub acute toxicity  
• Pharmacological activity of the Siddha formulation. 
• And Bio-Chemical analysis. 
 
 To conduct the clinical trial on the patients of Ukkara Soolai with a trial drug of 
Velvanga Parpam. 
 
 To find out the statistical analysis of the clinical study. 
 
 To handle the modern parameters to confirm the diagnosis and prognosis of the 
study. 
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REVIEW OF LITERATURE 
SIDDHA ASPECT 
 
  Siddha, the oldest system of Indian medicine has gone deep into the problem of 
the elderly people and it proposes mainly the ‘Kayakalpa’ treatment. The term 
‘Kayakalpa’ is derived from two Tamil words ‘Kaya’ which means the body and ‘Kalpa’ 
means the stone. Keeping the body as strong as a stone is the main aim of Kayakalpa. By 
this treatment the body gets free from the graying of hair, ageing, diseases etc.  
 In siddha, kaya kalpa treatment helps to prevent the ageing. But now a days ageing 
process in human being is a regular one. It includes degenerative diseases, hormonal 
diseases, neuro-muscular diseases, metabolic diseases etc. These ageing processes is 
called “MOOPPU” in siddha system and “GERIATRIC” in western medicine. The 
term geriatrics comes from the Greek, Geron meaning "old man" and Iatros meaning 
"healer". However, geriatrics is sometimes called medical gerontology. 
Life style modification is also an integral part of geriatric and “kaya kalpa” 
treatment. It includes proper food habits, sleep and relaxation, exercise, personal 
cleanliness, tension free and clear mind, entertainment etc. ‘Yoga’ and ‘Pranayama’ have 
got their own significance in dealing with this challenge. Research have proved, beyond 
doubt that these are efficacious in neuro-muscular, musclo-skeletal, respiratory, and 
psychosomatic and other health problems in elderly people. 
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UKKARA SOOLAI 
SOOLAI:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
DEFINITION: 
In general, Soolai can be defined as pricking or piercing pain that may occur in 
any part of the body. It is named according to the part of the body it arises.                                                                                                                                                      
Ukkara soolai is defined as pain arising during the time of Micturation or when the 
bladder is filling only in males. 
 
ETIOLOGY: 
 Etiology for Soolai has been described by many siddhars. They are as follows, 
General etiology for Soolai according to  
a) Yugimuni in Yugi vaithiya Sinthamani800: 
                   ‘rhh;thd #iytU khWNfsha; 
         jf;frpiwg; gl;bUf;Fe; jPik ahYk; 
          Mh;thd twr;RLNrh wUe;j yhYk; 
         mwTNk rypg;ghY Nkhl yhYe; 
          jhh;thd rigkpFe;j rz;ilahYk; 
         jifahd Jth;g;nghrpg;G Gifj;j yhYk; 
          Nth;thd Nkhfj;jpd; Gzh;r;rpahYk; 
         kpFe;jgrp AWjypdhw; #iy ahNk” 
 
                                         --a+fp itj;jpa rpe;jhkzp 800-gf;fk; 84 
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   ‘Mnkd;w td;dj;Jf; fpWjp gz;zp 
           ajpfgu Njrpfis abj;j Ngh;f;Fq;  
             fhnkd;w fw;Gila kq;if khiuf; 
         fUjpNa kdj;Jspr; rpj;j Ngh;f;Fk; 
                       thnkd;w tho;kuj;ij ntl;b Ndhh;f;Fk; 
          topkwpj;J nghUs;gwpj;j kjpNf lh;f;Fk;  
                  Vnkd;w vr;rpwidf; fth;e;j Ngh;f;Fk; 
           ,fj;jpNy Nehnta;jpr; #iy ahNk” 
 
                                         --a+fp itj;jpa rpe;jhkzp 800- gf;fk; 85  
                      
                    
• Imprisonment 
• Consumption of hot diets 
• Depression 
• Exhaustive running 
• Anxiety 
• Excessive consumption of astringent diets 
• Indulgence in excessive intercourse 
• Excessive starvation 
• Ill treating the physically and mentally deserving people 
• Deforestation 
• Winding other people things (Robbery) 
• Giving their eaten left over’s to others 
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b) Guru naadi sasthiram: 
     ‘#iy tUk;thwjidr; nrhy;yf; Nfz;Nkh 
    Rw;wpaNjhh; tpireuk;gpy; NtTfz;L 
       fhiyANk A+LUtpj; jkh;jhd; tpk;kpf; 
   fspg;gJNghy; khRgw;w apuj;jk; tw;wp 
       khiyaJ Nghy;njhLj;J euk;gpd; kPNj 
   tifahd tpireuk;ig klf;fpf; nfhs;Sk; 
       Nfhiytpl;l FUliug;Nghy; jpl;lkpe;J 
    Fbf;nfLf;FQ; #iyaJ Fwpfz;BNu” 
 
                                                    - FUehb E}y;- gf;fk;-235 
 
Vatha force ,one among the three vital force is disturbed and penetrates through 
the nerves and affects the Senneer thathu(Blood) resulting in deterioration of blood and 
produces stress in the body. The Soolai settles in the body as a blind man without stick 
and destroys the body and life. 
c) Agathiyar in Gunavagada thirattu: 
              ‘jpUj;jkha; thjj; NjhNl 
       jPq;nfhL gpj;jQ; Nrhpy; 
              nghUj;Jfs; NjhWk; nehe;J 
        NghjNt gpbf;FQ; #iy 
               nghUe;jplh thA nfhs;Sk; 
        Ngrpa thNw NehFk; 
               fUj;jpdhy; mwpe;J ed;wha;  
          fz;blha; kdpjh;f; nfy;yhk;” 
       - mfj;jpau; Fzthflk;- gf;fk;-26 
 
The above literature describes that the dearrangement of Vatham along with 
Pitham will cause pain in all the joints and this condition is indicated as Soolai. 
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d) Thanvanthiri in Therayer vagadam: 
        ‘mq;fj;jpnyz;nza; Nja;j;J KOFk;eh shpitNrhpw; 
  rq;fj;jpw; Rf;fpyj;ijj; jk;gpf;fpw; Wiyele;j 
       gq;fj;jpw; grpapw;fl;f gjhh;j;jj;jpy; kpFk;Gspg;gpy;  
  tq;fj;jpahr Njh\j;jpy; te;jpUQ; #iy” 
 
      ‘me;jzh; fw;Gkhj uUspa rhgj;jhY 
  Ke;jpa tpidapdhY Kjphp fh;g;gNkfj;jhYQ; 
       rpe;ijapw; nfhLikahYe; rptFU epe;ijahYk; 
           njhe;jkhk; tpahjpahYk; Njhd;wpLQ; #iyjhNd” 
 
                                                           -Njiuau; thflk;- gf;fk;333 
 
• Intercourse after oil bath 
• Semen arrest 
• Excessive intake of Sour and Astringent diets 
• Curse by a Chaste women 
• Karma, the result of deeds in past birth 
• Venereal diseases 
• Disrespect to Guru 
 
e) Jeevaratchamirtham (Sapapathi muthaliyar) 
• Depression 
• Exhaustive running 
• Anxiety 
• Intake of unpurified Mercurial drugs.  
• Excessive consumption of astringent diets 
• Indulgence in excessive intercourse 
• Excessive starvation.                                         
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CLASSIFICATION: 
The types of Soolai is named differently by many Siddhars. They are as follows, 
Yugimuni’s view in Yugi vaithiya Sinthamani 800: 
 Yugimuni classified the Soolai in to fifteen types. They are 
1. Mega Soolai 
2. Muri Soolai 
3. Vatha Soolai 
4. Pitha Soolai 
5. Iyya Soolai 
6. Aamma Soolai 
7. Ukkara Soolai 
8. Gunma Soolai 
9. Ularthu Soolai 
10. Nithamba Soolai 
11. Karai Soolai 
12. Sura Soolai 
13. Pakka Soolai 
14. Karppa Soolai 
15. Dhoora soolai
THEERUM AND ELITHIL THEERATHAVAI: 
 Theerum Soolai : 
1.  Dhoora soolai 
2. Mega Soolai                          
3. Vatha Soolai                          
4. Pitha Soolai                           
5. Ularthu Soolai                       
6. Karai Soolai 
7. Sura Soolai 
8. Pakka Soolai 
9. Karppa Soolai
 Elithil Theeratha Soolai : 
 1. Muri Soolai                                       
 2. Iyya Soolai                                     
 3. Aamma Soolai 
 4.Ukkara Soolai 
 5.Gunma Soolai 
 6.Nithamba Soolai
In Jeevaratchamirtham classification, therum therathavai of Soolai is same as in 
Yugivaithiya sinthamani. 
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Thirumoolar’s view: 
The Thirumoolar classified the Soolai into six types and these are further 
subdivided into eighteen types. They are as follows, 
‘MWtifr; #iyapy; mW%d;W Ngu;nrhy;thu;                                                                       
NtW kpijNay; ntt;NtW nkhd;Wkpy;iy                                                       
$Wk; ,jd;ehkk; Nfhb FzQ;nrhy;thu;                                                                                                                                                          
;NgW kW#iyg; Ngu;nrhd;dhu; ee;jpNa” 
                            -jpU%yu; Fzthflk;- gf;fk;-32 
 
      1. Vatha Soolai 
      2. Pitha Soolai.  
      3. Kapha Sool 
      4. Vatha pitha Soolai 
      5. Iyya pitha Soola 
      6. Iyya vatha Soolai 
 Anuboga vaithiya deva ragasiyam:. 
The Soolai is classified in of seven types. They are 
1. Vatha Soolai 
2. Pitha Soolai 
3. Kapha Soolai 
4. Thiri Soolai 
5. Aamma Soolai 
6. Surkkara Soolai 
7. Gunma Soolai 
8.  
Ukkar soolai is one among the fifteen type soolai noi.  
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CLINICAL FEATURES [NOI KURIGUNANGAL]: 
              The Clinical features of Ukkara soolai according to Yugimuni in yugivaithiya 
sinthamani 800: 
 
ÌòÐÓì ¸¡Ã Ý¨ÄÂ¢ý Ì½ó¾¡ý 
§¸¡÷¨ÅÂ¡ö Å¢Ä¡Å¾É¢ø ÓÐ¸¢ø ¦¿ïº¢ø 
«ò¾¢Â¢ø ¿¡À¢Â¢É¢ ÄÀ¡É Ì¾ò¾¢ø 
«¾¢¸òÐý Á¡í¸¢„ó¾¡ý ÅÇ÷óÐ §ÁÅ¢ô 
ÀòÐÁ½ü ÀÕì¨¸§À¡ü ºÄòÐ Å¡Ã 
À¾¢ ¦¿Õì¸¢ ãò¾¢ÃÁ¡íì ¸¢¡¢îº¢ Ôñ¼¡öò 
¾òÐº¼íì ¸Îô¦ÀÎòÐ Á¾¢¸ Äí¸¢ò 
¾Ç÷îº¢¦Â¡Î ÁÂì¸Á¡öò ¾ûÙó¾¡§É 
 
                                                  --a+fp itj;jpa rpe;jhkzp 800 Àì¸õ-68 
 
Clinical features of Ukkara soolai 
• Lower abdominal pain   
• Abdominal distension 
• Pricking pain present in the lower abdomen 
• Some abnormal growth developed in lower abdomen and it is 
compress the urinary tract.                                                                                                                              
• Burning micturation. 
• Frequency of urine. 
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The above symptoms that are present in other diseases are as follows: 
 
1. MOOTHIRA KIRICHARAM: 
According To Therayar Vaagadam: 
ãò¾¢Ãì ¸¢¡¢îº¢ì Ì½íì §¸Ç£÷ ÓÎÌó ÐÇ¢Â¡ö Å¢Æïîºü§È 
¬üÈ¢ò àÃõ ¿¼ì¸ ¦Å¡ð¼¡ ¾Ú¨Å ÁÕó¾¡ Ä¡üÚÅ¢Ìó 
àüÈ¢ Å¢¨ÇÅ¡ö Å¢¨Çó¾¢Õó¾¡ø ¾¨¼Â¡ø ¸Î¸¢ 
Á¡üÈ¢ÁÚì¸ Å¨¸ì ¸¡½ ÁÛ§Å¡÷ì ¦¸Ä¢É Ó¨ÃôÀ£§Ã. 
 
-§¾Ãý Å¡¸¼õ. - 168 
 
• Drippling of urine 
• The person cannot walk far distance due to frequency of urination. 
• And it may be cured in surgical treatment also. 
 
2. VAATHA SOOLAI: 
According To Gunavaagada Thirattu: 
¿¢¨ÄÂ¡É Å¡¾ò¾¢ø ¿¢ýÈ¢Îï Ý¨Ä ¾¡ý 
Ý¨ÄÂ¡É ¨¸ì¸¡ø Ì¨Çîº¦ÄøÄ¡õ Òñ§À¡ø 
¸¨ÄÂ¡Á ¦ÄòÐì ¸ñ ¸½ò¾¢Îíì ¸£ú Å¡§Â¡Î 
¾¨ÄÂ¡É §ÁÉ¢ ¾¡ý þ¨Çò ¾¢Î§Á.. 
- Ì½Å¡¸¼ò ¾¢ÃðÎ Àì¸õ -73 
• Pricking pain is present in extremities 
• It affects the “Abanan”. That is, it also affects Micturation and 
Defication. 
 
19 
   
3. AZHAL NEER SURUKKU: 
 
 
            ¾¡ý ãò¾¢Ã Á¢¸îº¢ ÅìÌó 
¾Ç÷óÐ§Á ¨¸¸¡Ö Áº¾¢ Â¡Ìõ 
À¡ÉÕì¸¢î º¢Ú¸Ä¡ ÂÕÅ¢ À¡Ôõ 
À¡ÃÁ¡íì Ì¾Áñ¼ Á¢Ä¢í¸ó ¾¡Ûíì 
¸¡ýÅ¡Ô ¾¡ýÁ£È¢ ÅÂ¢ÚÓôÒõ 
¸Ç¸¦ÇýÚ þ¨ÃîºÄ¡öì ¸ºí¸¢ §ÂÚõ 
§Åû¸¡Ô Å¡ÔÄ÷óÐ Á¢Ãðº¢ Â¡Ìõ  
Å¢ÎõÀ¢ò¾ ãò¾¢Ãò¾¢ý Å¢ÅÃó¾¡§É. 
 
- ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢- 431 
  
• Burning micturation 
• Tiredness of upper and lower limbs 
• Oliguria 
• Pricking pain is present in genital area and anal region. 
• Abdominal discomfort 
• Dryness of mouth 
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MUKKUTRA VAERUPADUGAL :( Pathogenesis) 
Disease occurs due to the derangement in 
•  Uyir thathukkal  
•  Udalthathukkal   
•  kala marupadu(seasonal changes) 
• Thinai( living lands ) and 
• Udal vanmai. 
 
UYIR THATHUKKAL: 
Mukkutra Iyal : 
The function of the three uyir thathus:  
a) Vali   –  (Kattru + Veli) 
 
b) Azhal   – (Thee) 
 
c) Iyyam   – (Neer+Mann) 
 
The alteration of three thathu in their reaction to extrinsic or intrinsic factors 
results in disharmony. This altered harmony and balance variation of the three thathus 
results in disease. Their natural ratio (1 :½:¼) to each other is discerned by the physician 
at the wrist and each nadi is individually assessed for its strength, speed and regularity. 
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The following poem describes the origin of three Uyir Thathus 
  ‘,Ug;ghd ehb vOgNjhBuh 
 apukhd Njfj;jpy; Vyg; -ngUehb 
 xf;fj; jrkj; njhopiy a+f;f jrthAf;fs; 
 jf;fgbahdNj  rhu;G” 
 
‘rhUe; jrehb jd;dpy; %yk; %d;W 
 NgUkplkp gpq;fiyAk; gpd;dYld;-  khWk;  
 ciuf;ftpuw; fhw;nwhl;Lzu;j;J Nkehrp 
 tiur;Rop Nahikaj;jpy; te;J” 
 
‘te;jfiy %d;wpy; tha;thkghdDld; 
 je;j gpuhzd; rkhdDk; re;jKwf; 
 $l;Lwtpy; Nurpj;jy; $Wk; thjk; gpj;jk;; 
 ehl;Lq;fgNk ahk; ehL” 
 
- fz;Zrhkpak;- gf;fk; 36 
  The three Thathus are manifested at the wrist and are individually and collectively 
assessed. These three humour are divided in to various types and have their functions 
specifically. 
FUNCTIONS OF VALI:  
 
‘xOq;Fls; jhNjo;%r; Nrhq;fp ,aq;f 
vOr;rpngw vg;gzpAk; Mw;w - vOe;fpupa 
Ntfk; Gyd;fSf;F Nktr; RWRWg;G 
thfspf;Fk; khe;ju;f;F thA” 
- kUj;Jt jdpg;ghly;  gf;fk;12 
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According to the physiological function, vali is ten types. They are  
S.NO VATHAM GENERAL FEATURES 
CHANGES IN 
UKKARASOOLAI 
1. Piranan(Uyir Kaal)  
Responsible for 
respiration and it is 
necessary for proper 
digestion  
 
Normal 
2. Abanan(Kizhnokkumkaal) 
Responsible for  all 
downward forces such as 
voiding of urine, stools, 
semen, menstrual flow  
 
Affected 
3. Viyanan(paravukaal) 
Dwells in the skin and is 
concerned with the sense 
of touch... extension and 
flexion of the parts of the 
body and distribution, of 
the nutrients to various 
parts of the body 
 
Affected 
4. 
Uthanan 
(melnokkukaal) 
Responsible for all kinds 
of upward motion such as 
nausea, vomiting etc... 
 
Normal 
5. Samanan(nadukkaal) 
Considered essential for 
proper digestion, 
assimilation and carries 
the digested nutrients to 
each and every organ 
 
Normal 
6. Nagan  
Helps in opening &closing 
of eyelids 
 
 
Normal 
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7. Koorman  
Responsible for vision, 
lacrimation  and yawning 
 
Normal 
8. Kirugaran 
Induces  appetite, 
salivation, all secretions in 
the body including nasal 
secretion and sneezing 
 
Normal 
9. Devathathan  
Induces and stimulates a 
person to become alert, get 
anger, to quarrel, to sleep 
etc 
 
Affected 
10. Dhananjeyan  
Resides in the cranium 
and produces bloating of 
the body after death. This 
leaves from the body after 
3days of death, forming a 
way through the skull. 
Normal 
 
In Ukkara soolai, Abanan, Viyanan and Devathathan will be mainly affected. 
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FUNTIONS OF AZHAL: 
 
 ‘grpjhfk; Xq;nfhspfz; ghu;itgz; lj;J 
 Urpnjup rj;jp ntk;ik tPuk; - crpj 
 kjp$u;j;j Gj;jptdg; gspj;Jf; fhf;Fk; 
 mjpfhup ahq;fh doy;” 
-  kUj;Jt jdpg;ghly; gf;fk;16 
 
Azhal is functionally divided in to five types. They are 
 
S.NO PITHAM NORMAL FEATURES 
CHANGES IN 
UKKARASOOLAI 
1. Anarpitham(Akkuanal) 
Peps up the appetite and 
aids in digestion. 
Normal 
2. Ranjagapitham(Vanna eri) 
Responsible for the color 
and contents of blood. 
Normal 
3. Sathagapitham(Attralangi) 
Controls the whole body 
and is held responsible for 
fulfilling a purpose. 
Affected 
4. Pirasagapitham(Ollolithee)  
Dwells in the skin and 
concerned with the shine, 
glow, texture and its 
complexion 
Normal 
5. 
Alosagapitham(Nokku 
Azhal) 
Responsible for the 
perception of vision. 
Normal 
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In Ukkara soolai, sathaga pitham will be affected. 
FUNTIONS OF IYAM: 
‘jplkPA nkd;gpizg;Gj; jpz;ikAw;w ahg;Gk; 
mlNyu; tOtOg;Gk; Mf;iff; - fplu;f;F 
ntUthg; nghWikAk; Nkyhd fhg;ghk; 
ngUikj;jh ikankdg; NgR” 
- kUj;Jt jdpg;ghly; gf;fk;20 
 
It is of five types. They are 
     
  
S.NO KABHAM GENERAL FEATURES 
CHANGES IN 
UKKARASOOLAI 
1. 
Avalambagam(Alli 
Iyyam)  
Lies in the respiratory organs, 
exercises authority over other 
khapas and controls the heart 
and circulatory system. 
Normal 
2. 
Kilethagam(Neerpi 
Iyyam)  
Found in stomach as its seat, 
moistens the food, softens and 
helps to be digested. 
Normal 
3. 
Pothagam(Suvaikanna 
Iyyam)  
Hold responsible for the sensory 
perception of taste. 
Normal 
4. 
 
 
Tharpagam(Niraivu 
Iyyam)  
Presents in the head and is 
responsible for the coolness of 
the eyes, sometimes may be 
referred to as cerebrospinal fluid 
Normal 
5. 
Santhigam(Ondri 
Iyyam)  
Necessary for the lubrication 
and the free movements of 
joints. 
Normal 
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UDAL KOORUGAL (SEVEN PHYSICAL CONSTITUENTS): 
‘,ukpuj; je;jir nea; epznkd;G kr;irtPe;njd;NwOk; KiwNa” 
 rujnkhL nka;kdj;J epiwTjUk;capUl;Lj;jhq;fp apUf;Fk; 
 cuKjTk; NkLgs;sk; epuTk; nea;g; gira+l;Lk; Xq;fp epWj;Jk;  
 gue;njd;gpd; JisfnlhWk; epuk;gpLq;fs; KisNjhd;wg; gz;Zk; njuptha;” 
       -rpj;j kUj;J}thq;fr; RUf;fk; -gf;fk;334 
The human body is made of seven basic physical constituents. These constituents 
should be in harmony and function normally. Any variation in them will lead to their 
functional deviations.The Natural characters of the seven physical constituents 
S.NO UDAL KATTUGAL GENERAL FEATURES 
CHANGES IN 
UKKARASOOLAI 
1. Saaram  (digestive essence) 
Responsible for the growth& 
development. It keeps the 
individual in good temperament 
and it enriches the bood. 
Normal 
 
2. Senneer (blood) 
Responsible for the colour of 
blood and for the intellect, 
nourishment, strength, vigour 
and valour of the body.  
Normal 
3. Oon (muscle) 
Gives lookable contour to the 
body as needed for the physical 
activity. It feed the fat next day 
and gives a sort of plumpness to 
the body  
Affected 
4. Kozhuppu (fat) Lubricates the organs to facilitate frictionless functions. Affected 
5. Enbu (bones) 
Supports & protects the vital 
organs, gives the definite 
structure of the body and 
responsible for the posture and 
movements of the body 
Normal 
6. Moolai (bone marrow) 
Nourishes the bone marrow and 
brain which is the centre that 
controls other systems of body 
Normal 
7. Sukkilam/ Suronitham(sperm/ ova) 
Responsible for reproduction Normal 
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THE VARIATIONS OF THE PHYSICAL CONSTITUENTS: 
1. SAARAM  
           Increased Saaram:Leads to diseases of increased kapham like indigestion Etc 
            Decreased Saaram : Leads to loss of weight, tiredness, lassitude, dryness of the 
skin and diminished activity of the sense organs. 
2. SENNER 
 Increased Senner : Causes boils in different parts of the body throbbing pain, 
anorexia, mental disorder, splenomegaly, Colicky pain., increased blood pressure, reddish 
eye and   Skin, jaundice, haematuria etc. 
 Decreased Senner : Leads to anaemia, tiredness, neuritis and lassitude, Pallor of 
body. 
3. OON  
 Increased Oon : Oon in excess causes cervical lymph adenitis, venereal ulcer, 
tumour in face, abdomen, thigh genitalia etc are the signs of increased Oon 
 Decreased Oon : Leads to impairment of sense organs, joints jaw, thigh and 
genitalia gets shortened 
4. KOZHUPPU 
 Increased Kozhuppu: Identical to that of increased Oon associated with Dyspnoea 
and loss of acidity 
 Decreased Kozhuppu: Leads to pain in the hip region and diseases of the spleen 
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5. ENBU 
 Excess Enbu : Growth in bones and teeth 
 Decreased Enbu : Loosening of teeth and nails and Splitting and falling of hair 
6. MOOLAI 
 Increased Moolai : Causes heaviness, swollen eyes, swollen phalanges, Oliguria 
and non healing ulcers 
 Decreased Moolai : Causes osteoporosis and sunken eyes 
7. SUKKILAM / SURONITHAM 
 Excess Sukkilam/Suronitham : Causes lust towards women and cause Urinary 
calculus 
 Decreased Sukkilam/Suronitham : Causes failure in reproduction, pain in the 
genitalia. 
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KAALA MARUBADUGAL: 
PARUVAKALAM (SEASONS): 
              According to ancient tamilians, the one year is divided in to six seasons and each 
season consists of two months and the year starts from Margazhi. 
S.NO KAALAM TAMIL MONTHS MUKKUTTRA   
MARUPAADUGAL 
1. Kaar Kaalam Aavani & Purattasi 
Aug 16 To Oct15 
VATHAM-Vettunilai 
Vazharchi 
PITHAM-Thanilai Vazharchi 
2. Koothir Kaalam Iypasi &Karthigai 
Oct 16 To  Dec15 
VATHAM- Thanilai Vazharchi 
PITHAM- Vettunilai 
Vazharchi 
3. Munpani Kaalam Margazhi & Thai 
Dec16 To Feb15 PITHAM- Thanilai Vazharchi 
4. Pinpani Kaalam Masi& Panguni 
Feb16 To June15 
KABHAM- Thanilai 
Vazharchi 
5. Elavenir Kaalam Chithirai & Vaikaasi 
April16 To June15 
KABHAM- Vettunilai 
Vazharchi 
6. Mudhuvenir Kaalam Aani & Aadi 
June16 To Aug 15 VATHAM- Thanilai Vazharchi 
THINAI (LAND): 
            Siddhars classified the lands in to five types. They are 
1. Kurunchi    - Mountain range 
2. Mullai         -Pastoral area of the forest 
3. Marudham -The fertile river bed 
4. Neidhal      -The coastal region 
5. Paalai         - Arid desert                                               
• The winter season gives good health to the man, early summer and latter rainy 
gives moderate health. Whereas early rainy and latter summer are more prone to 
diseases, that’s why siddhars called it as Aanaga kalam 
• Marudha nilam is the fertile area where no disease occurs 
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RELATION BETWEEN MUKKUTRAM, KAALANGAL AND THINNAIGAL                                                                                                                                                                         
 
  
  
MUKKUTRAM 
               PARUVAKALAM(SEASONS)                  
THINAI                         
Thannilai 
vazharchi 
(Accumulation) 
Vaetrunilai 
vazharchi        
(Aggravation) 
Thannilai 
adaithal             
(Alleviation) 
 
 
VATHAM 
 
 
Mudhuvenil 
kalam 
 
 
Kaar kalam 
 
 
 
 
Koothir kalam 
 
 
Vatha disease 
is more 
prevalent in 
Neidhal land 
 
 
PITHAM 
 
 
Kaar kalam 
 
 
Koothir kalam 
 
 
Munpani 
Pitha disease 
is more 
prevalent in 
Mullai land 
 
 
KAPHAM 
 
 
Pinpani 
 
 
Elavenil kalam 
 
 
Mudhuvenil 
kalam 
Kaphadisease 
is more 
prevalent in  
Kurunchi 
land 
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  UDAL VANMAI (IMMUNITY): 
            Siddhars classify Udal vanmai as three types. They are 
1. Iyarkai vanmai 
2. Kala vanmai 
3. Seyarkai vanmai 
           Since Ukkara soolai patients are suffering with pain as principal symptom, we 
came to understand that it is because of alteration in Vali thathu and Vali should be the 
primary causative factor (Muthanmai kutram). It can be confirmed by the words of great 
Siddhar Therayer 
                   ‘neLthj rhHgJTkpd!wp !#iy tuhJ” 
PINIYARI MURAIMAI (DIAGNOSIS): 
           It means the method of diagnosing the disease.           
         ‘kjpj;jplw;fUik tha;e;j 
                   khz;gupfhunky;yhe; 
            Jjpj;jpl Tzu;e;jhNdDe; 
                  Jfswg; gzpapd;wd;ik 
            gjpj;jpl Tzuhdhfpw; 
                  gaDwhdhfhyhNd 
            tpjpj;jpL gpzpj;jpwj;ij 
                  tpsk;GJ Kjw;fz;kd;Ndh” 
 
- rpfpr;rh uj;jpdjPgk;- gf;fk; 3    
                                      
              The above poem describes that diagnosis is very important for the physician to 
treat the disease. 
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And, 
 
§¿¡ÂÈ¢óÐ §¿¡ö Ó¾Ä¢ §¿¡ì¸È¢óÐ §¿¡Ô¾ý 
¾¡ÂÈ¢óÐ §À¡ìÌó ¾¡ÁÈ¢óÐ ¸¡Â¿¢¨Ä 
¦¿¡ó¾Æ¢Â¡ Åñ½ ¸÷Å¢ôÀ¡÷ §¿¡Â¢É÷ìÌ 
¾ó¨¾¦ÂÐ ¿üÀñÊ¾÷ 
-§¾Ãý ¦ÅñÀ¡ Àì¸õ-11  
 
Four steps are followed in diagnosing the disease. They are, 
a. Poriyaal arithal 
b. Pulanal therthal 
c. Vinaathal 
d. Envagaithervu  
In detail, 
a. Poriyaal arithal: 
                     In this the physician should carefully observe the changes that occur in the 
five sensory organs (Porigal) of the patient. 
b.Pulanal therthal: 
                 The physician carefully applies his five senses of perception, smell, taste, 
vision, touch and sound to understand the condition of the patient. 
c.Vinaathal: 
                 The physician should interrogate about the patients name, age, 
occupation,socio economic status, food habits, history of past illness, history of present 
illness, family history, marital status, menstrual history and frequency of pain. 
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ENVAGAI THERVUKAL 
‘eh epwk; nkhop tpop ky%j;jpuk; 
 ehb guprkpit kUj;JtuhAjk;” 
-Neha;ehly; Neha; Kjdhly;-253 
 
¿¡ÊÂ¡ø Óý§É¡÷ ¦º¡ýÉ ¿ø¦Ä¡Ä¢ À¡¢ºò¾¡Öõ 
¿£ÊÂ Å¢Æ¢Â¢É¡Öõ ¿¢ýÈ ¿¡ìÌÈ¢ôÀ¢É¡Öõ 
Å¡ÊÂ §ÁÉ¢Â¡Öõ ÁÄ¦Á¡Î ¿£¡¢É¡Öõ 
ÝÊÂ Å¢Â¡¾¢¾ý¨Éî Í¸Ó¼ý «È¢óòÐÀ¡§Ã 
- ¾¢ÕÁó¾¢Ãõ - 10õ ¾¢ÕÁ¨È                    
 
Nowadays advanced diagnostic tools have been developed by modern bio-medical 
scientists. But Siddhars have given eight diagnostic methodological tools. They are called 
as Envagai thervu. 
Eight fold system of clinical assessments 
Siddhars have given eight diagnostic methodological tools. They are, 
1. Naa 
2. Niram 
3. Mozhi 
4. Vizhi 
5. Malam 
6. Moothiram 
7. Naadi 
8. Parisam 
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GENERAL FINDINGS: 
1. NAA: 
i. Signs and symptoms in the tongue are noted here. 
ii. Color, salivary secretion, ulcers, coating, inflammation, taste 
changes, deviation and its nature are generally noted. 
       In Ukkara soolai the naa didn’t have any impact. 
 
2. NIRAM: 
The color of the skin is noted here. 
          In Ukkara soolai the niram didn’t have any impact 
3.  MOZHI: 
Character of the speech is noted, mainly uratha olli(high pitched), 
thazhntha olli(low pitched), or resembles the sound of any 
instrument. 
In Ukkara soolai the mozhi will be affected to the patients who have severe 
pain leading to the thazhntha olli 
4. VIZHI: 
Character of the eye is noted. Color, Warm, Burning Sensation, 
Irritation, Visual Perception.   
     In Ukkara soolai the vizhi didn’t have any impact. 
5. MALAM: 
The stools are examined for quantity; hardening (malakattu), loose 
motion (bethi), Color and smell. 
   In Ukkara soolai the malam will be affected in severe enlargement. 
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 6. MOOTHIRAM: 
    A. NEERKURI: 
The urine is examined for its color, odour, volume, froth and weight. 
 In Ukkara soolai the moothiram will be affected due to urinary micturation. 
    B.NEIKURI 
 
‘mUe;J khwp ujKk; mtpNuhjkjha;  
  mf;fy; myu;jy;mfhyt+d; jtpu;jow; 
 Fw;wstUe;jp cwq;fp itfiw 
 Mbf;fyrj; jhtpNa fhJnga; 
 njhUK$u;j;jf; fiyf;Fl;gL ePupd; 
 epwf;Fwp nea;Fwp epUkpj;jy; flNd” 
       -rpj;j kUj;Jthq;fr; RUf;fk; - gf;fk;509  
                      
              The early morning urine of the patient is analyzed by dropping a drop of gingely 
oil on the surface of the urine sample. The accumulation, formations, changes, and 
dispersal under the sunlight without any external disturbances of the urine sample can be 
noted.  
• Vatha neer - The oil spreads like snake 
• Pitha neer - The oil spreads like ring 
• Kapha neer - The oil spreads like pearl 
• If the oil spreads gradually, it indicates good prognosis 
• If the oil spreads fast or gets mixed completely with urine or sinks in urine, it 
suggests bad prognosis. 
Since Ukkara soolai is due to the derangement of vatham and pitham,the neikuri will 
be vatha or pitha neer. 
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7. NAADI: 
             Naadi is a Unique Siddha Pulse reading method and it should be felt and not 
read. Different gaits of Vazhi , Azhal, Iyam  like branching, jumping, mixing, rotating 
and compression can be identified. 
NAADI NADAI: 
 
     ‘ghu;f;fNt ngz;fSf; fplJgf;fk; 
      gjpthfg; ghu;j;jplNt gfugf;NfSk; 
      fhu;fNt thjkJ ru;g;gk; Nghyha; 
      fdkhd gpj;jkJ jtis NghyhQ; 
      Nru;f;fNt iaankd;w ehbjhDQ; 
      rpWeilah td;dk; Nghw; nropg;gha;f; fhDk;” 
-gjpnzd; rpj;ju; ehbrhj;jpuk; (gupG+uz ehb)-  gf;fk;2 
 
 
IDENTIFICATION 
(FINGER) 
 
INDEX 
 
MIDDLE 
 
RING 
 
STRENGTH (IN UNIT) 
 
1 
 
1|2 
 
1|4 
 
 
PATTERN 
 
 
 
MALE 
 
Hen 
 
Tortoise 
 
Snake 
 
FEMALE 
 
Snake 
 
Frog 
 
Swan 
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In Ukkara soolai the Naadi nadai will be as follows; 
Vatha naadi: 
      ‘thjnkDk; ehbaJ Njhd;wpw; rPjk;…... 
              jpus;thA #iy typf;fLg;Gj; jpiu” 
Kappa pitham: 
         ‘fhZklh #iynad;why; Nrj;Jkgpj;jk;” 
Vatha kappam: 
        ‘ghq;fhd thjj;jpy; Nrj;Jkehb... 
           Nru;e;jtplk; ntb#iy....” 
Pitha vatham: 
        ‘rpwg;ghd gpj;jj;jpy; thjehb.... 
            ciwg;ghfr; nrupahik Fd;kQ; #iy” 
Kappa vatham: 
         ‘fz;lhNah rpNyw;gdj;jpy; thjehb.... 
              tplghfk; tpl#iy gf;fthjk;” 
- rjf ehb 
- Neha;ehly; Neha; Kjdhly;-253 
Vatha pitham: 
          ‘jpUj;jkhk; thjj;NjhNl j_q;nfhL gpj;jQ; Nrupy; 
             nghUj;Jfs; NjhWk; nehe;J NghjNt gpbf;FQ; #iy” 
 - Fzthfl ehb(mfj;jpau;)-ghly; 26 
 In Ukkara soolai the Naadi can be vatha naadi, vatha pitham, vatha kappam, pitha 
vatham, kappa vatham, kappapitham. 
8. PARISAM:  
Observations as touch, temperature, sensory impairment, masses, nodes, swelling, 
and texture of the skin, pain, hardness, edematous, and dullness shall be noted. 
 
In Ukkara soolai the parisam may be affected in the lower abdomen severe pain. 
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LINE OF TREATMENT: 
 
MEDICINE: 
 For Treatment: 
I. Velvanga Parpam: 
- 65 mg, Twice Daily. 
- With Butter. 
DURATION OF TREATMENT: 
            15 days medicine with pathiyam, 
 Next 15 days pathiyam without medicine. 
 
 PATHIYAM AND APATHIYAM: 
 
A. Pathiyam(diet): 
Early morning: 
            A glass of luke warm water mixed with the half of the lime and a spoon of honey. 
Diet: 
• Rice: Kaar, Kuruvai, Manakathai, Boiled rice (any one) 
• Soy and other foods like legumes, tea, apples and onions may help prevent or 
treat the symptoms. 
• Increase intake of fruits, vegetables and whole grains, soy, and green tea, 
foods rich in omega 3 oils (cold-water fish – salmon, sardines, mackerel) and 
in zinc (raw pumpkin seeds for omega-3 and zinc) 
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B. Apathiyam(Avoid): 
 
• Reduce foods high in fat and cholesterol (butter and margarine, beef and 
whole milk), sweet foods, and refined carbohydrates (white bread and white-flour 
pasta) 
• Avoid or decrease intake of alcohol, coffee, and beer, particularly after dinner, 
and tobacco. 
• Hot and sour tastes 
• Kizhangu vagai(tubers), Vatha foods. 
 
5. ADVICE: 
1. Some men who are nervous and tense urinate more frequently. Reduce stress by 
exercising regularly and practicing relaxation techniques such as meditation. 
 
2. When you go to the bathroom, take the time to empty your bladder completely. 
This will reduce the need for subsequent trips to the toilet. 
 
3. Talk with your doctor about all prescription and over-the-counter medications you 
take; some may contribute to the problem. Your doctor may be able to adjust 
dosages or change your schedule for taking these drugs, or he or she may prescribe 
different medications that cause fewer urinary problems. 
 
4. Avoid drinking fluids in the evening, particularly caffeinated and alcoholic 
beverages. Both can affect the muscle tone of the bladder, and both stimulate the 
kidneys to produce urine, leading to nighttime urination. 
 
 Yoga practice 
- Pranayamam 
- Sarvangasanam 
- Dhanurasanam 
- Halasanam  
- Yogamuthirai. 
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6. PREVENTION: 
• Balanced & Low fat diet 
• Regular exercise 
• Suriya namesakaram 
• Oil bath twice in a week 
• Avoid Junk foods 
• Avoid tobacco, Alcohol 
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Modern Aspects 
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MODERN ASPECT 
Introduction:  
Benign Prostatic Hyperplasia is the most common benign tumor in men, and its 
incidence is age-related. Benign Prostatic Hyperplasia (BPH) is a progressive condition 
characterised by prostate enlargement accompanied by lower urinary tract symptoms 
(LUTS). It contributes to, but is not the sole cause of LUTS. It is well known that BPH 
and the resultant LUTS is very common in elderly men  
 It was estimated that in the male population. Although clinical evidence of disease 
occurs less commonly, symptoms of prostatic obstruction are also age-related. At age 55, 
approximately 25% of men report obstructive voiding symptoms. At age 75, 50% of men 
complain of a decrease in the force and calibre of their urinary stream.  
Consideration of prostatic diseases will be facilitated by a brief introduction to the 
normal anatomy of the prostate.  
Anatomy of the Prostate Gland: 
The prostate is a Greek word. Prostate literally means "one who stands before", 
"protector" or "guardian”.Which adds secretions to the sperm during 
the ejaculation of semen. 
In 2002, female paraurethral glands, or Skene's glands, were officially renamed the 
female prostate by the Federative International Committee on Anatomical Terminology. 
Shape: 
It is a Chestnut-shaped or conical reproductive organ and it is partly glandular and 
partly muscular body. 
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Location: 
It is situated in the pelvic cavity located directly beneath the bladder in the male. 
And it is placed immediately below the internal urethral orifice and around the 
commencement of the urethra. 
Development: 
The prostatic part of the urethra develops from the pelvic part of the urogenital 
sinus or endodermal origin.  
 
Dimension: 
 The prostate measures about 4 cm. transversely at the base, 2 cm. in its antero-
posterior diameter, and 3 cm. in its vertical diameter. Its weight is about 8 gm. 
Features: 
 It has 2 parts and 4 surfaces. 
•  A base, an apex,  
•  An anterior, a posterior and two lateral surfaces. 
Base: 
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 The base is directed 
upward, and is applied to the 
inferior surface of the 
bladder, The greater part of 
this surface is directly 
continuous with the bladder 
wall; the urethra penetrates it 
nearer its anterior than its 
posterior border. 
Apex: 
          The apex is directed 
downward, and is in contact 
with the superior fascia of the 
urogenital diaphragm. 
Surfaces: 
Posterior surface: 
  The posterior surface is flattened from side to side and slightly convex from 
above downward; it is separated from the rectum by its sheath and some loose connective 
tissue, and is distant about 4 cm. from the anus. Near its upper border there is a 
depression through which the two ejaculatory ducts enter the prostate.  
This depression serves to divide the posterior surface into a lower larger and an 
upper smaller part. The upper smaller part constitutes the middle lobe of the prostate and 
intervenes between the ejaculatory ducts and the urethra, it varies greatly in size, and in 
sme cases is destitoute of glandular tissue. The lower larger portion sometimes presents a 
shallow median furrow, which imperfectly separates it into a rightand a left lateral lobe: 
these form the main mass of the gland and are directly continuous with each other behind 
the urethra. 
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 In front of the urethra they are connected by a band which is named the isthmus: 
this consists of the same tissues as the capsule and is devoid of glandular substance. 
Anterior surface:  
  The anterior surface measures about 2.5 cm. from above downward but is 
narrow and convex from side to side. It is placed about 2 cm. behind the pubic 
symphysis, from which it is separated by a plexus of veins and a quantity of loose fat. It 
is connected to the pubic bone on either side by the puboprostatic ligaments. The urethra 
emerges from this surface a little above and in front of the apex of the gland. 
Lateral surfaces:  
  The lateral surfaces are prominent, and are covered by the anterior portions 
of the Levatores ani, which are, however, separated from the gland by a plexus of veins. 
 The prostate is perforated by the urethra and the ejaculatory ducts. The urethra 
usually lies along the junction of its anterior with its middle third. The ejaculatory ducts 
pass obliquely downward and forward through the posterior part of the prostate, and open 
into the prostatic portion of the urethra. 
Structure: 
The gland surrounds the urethra, the duct that serves for the passage of both urine 
and semen, rounded at the top, the gland narrows to form a blunt point at the bottom, or 
apex.  
The prostate is immediately enveloped by a thin but firm fibrous capsule, distinct 
from that derived from the fascia endopelvina, and separated from it by a plexus of veins.  
This capsule is firmly adherent to the prostate and is structurally continuous with 
the stroma of the gland, being composed of the same tissues, viz., non-striped muscle and 
fibrous tissue. The substance of the prostate is of a pale reddish-gray color, of great 
density, and not easily torn. It consists of glandular substance and muscular tissue. 
Muscular tissue:  
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 The muscular tissue according to Kölliker, constitutes the proper stroma of the 
prostate, the connective tissue being very scanty, and simply forming between the 
muscular fibers, thin trabeculæ, in which the vessels and nerves of the gland ramify. The 
muscular tissue is arranged as follows, immediately beneath the fibrous capsule is a dense 
layer, which forms an 
investing sheath for the 
gland.Secondly, around 
the urethra, as it lies in the 
prostate, is another dense 
layer of circular fibers, 
continuous above with the 
internal layer of the 
muscular coat of the 
bladder, and blending 
below with the fibers 
surrounding the membranous portion of the urethra.  
Between these two layers strong bands of muscular tissue, which decussate freely, 
form meshes in which the glandular structure of the organ is imbedded. In that part of the 
gland which is situated in front of the urethra the muscular tissue is especially dense, and 
there is here little or no gland tissue; while in that part which is behind the urethra the 
muscular tissue presents a wide-meshed structure, which is densest at the base of the 
gland that is, near the bladder becoming looser and more sponge-like toward the apex of 
the organ.The prostate gland is a conglomerate of 30 to 50 tubular or saclike glands that 
secrete fluids into the urethra and ejaculatory ducts. The secretary ducts and glands are 
lined with a moist, folded mucous membrane. The folds permit the tissue to expand while 
storing fluids. Beneath this layer is connective tissue composed of a thick network of 
elastic fibres and blood vessels. The tissue that surrounds the secretary ducts and glands 
is known as , this contains muscle, elastic fibres, and collagen fibres that give the prostate 
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gland support and firmness. The capsule enclosing the prostate is also of interstitial 
tissue. 
Glandular substance : 
The glandular substance is composed of numerous follicular pouches the lining 
of which frequently shows papillary elevations. The follicles open into elongated canals, 
which join to form from twelve to twenty small excretory ducts. They are connected 
together by areolar tissue, supported by prolongations from the fibrous capsule and 
muscular stroma, and enclosed in a delicate capillary plexus. The epithelium which lines 
the canals and the terminal vesicles is of the columnar variety.  
The prostatic ducts open into the floor of the prostatic portion of the urethra, and 
are lined by two layers of epithelium, the inner layer consisting of columnar and the outer 
of small cubical cells. Small colloid masses, known as amyloid bodies are often found in 
the gland tubes. 
Vessels and Nerves: 
The arteries supplying the prostate are derived from the internal pudendal, 
inferior vesical, and middle hemorrhoidal. Its veins form a plexus around the sides and 
base of the gland; they receive in front the dorsal vein of the penis, and end in the 
hypogastric veins. The nerves are derived from the pelvic plexus. 
Function: 
The function of the prostate is to secrete a slightly acidic fluid, milky or white in 
appearance, that usually constitutes 50–75% of the volume of the semen along with 
spermatozoa and seminal vesicle fluid. Semen is made alkaline overall with the 
secretions from the other contributing glands, including, at least, the seminal vesicle 
fluid. The alkalinity of semen helps neutralize the acidity of the vaginal tract, prolonging 
the lifespan of sperm. The alkalinization of semen is primarily accomplished through 
secretion from the seminal vesicles.  
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The prostatic fluid is expelled in the first ejaculate fractions, together with most of 
the spermatozoa. In comparison with the few spermatozoa expelled together with mainly 
seminal vesicular fluid, those expelled in prostatic fluid have better motility, longer 
survival and better protection of the genetic material.The prostate also contains some 
smooth muscles that help expel semen during ejaculation. 
Secretion: 
Prostatic secretions vary among species. They are generally composed of simple 
sugars and are often slightly acidic. 
In human prostatic secretions, the protein content is less than 1% and includes 
proteolytic enzymes, prostatic acid phosphatase, beta-microseminoprotein, and prostate-
specific antigen. The secretions also contain zinc with a concentration 500–1,000 times 
the concentration in blood. 
Female prostate gland: 
The Skene's gland, also known as the paraurethral gland, found in females, 
is homologous to the prostate gland in males. However, anatomically, the uterus is in the 
same position as the prostate gland. In 2002 the Skene's gland was officially renamed to 
female prostate by the Federative International Committee on Anatomical Terminology.  
The female prostate, like the male prostate, secretes PSA and levels of this antigen 
rise in the presence of carcinoma of the gland. The gland also expels fluid, like the male 
prostate, during orgasm. 
The only three pathological processes that affect the prostate gland. There are 
Inflammation, Benign enlargement, and tumors. Of these three, the benign prostatic 
enlargement(BPH) are by far the most common and occur so often in advanced age that 
they can almost be constructed as a “normal” ageing process. 
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Benign Prostatic hyperplasia 
Introduction: 
The noncancerous enlargement of the prostate called Benign prostatic hyperplasia 
(BPH). It affects nearly all men reaching normal life expectancy. BPH is common in 
older men. By the age 60, more than half of men have BPH. By the age 85, about 90% of 
men have BPH, but only 30% of men will be bothered by their symptoms. 
BPH affects the inside part of the prostate first. Enlargement frequently causes a 
gradual squeezing of the urethra where it runs through the prostate. 
Sometimes this causes difficulty in urinating or other urinary problems. BPH 
generally does not interfere with sexual functioning. 
BPH is not cancer nor does it lead to cancer. However , it is possible for a men to 
have both BPH and prostate cancer. 
Definition:  
BPH is a noncarcenogenic (benign) growth of the cells within the prostate gland. 
From 40 years of age the prostate increase in volume by 2.4 cms qube per year on 
average. The process begins in the periurithral (tranitional) zone and involves both 
glandular and stromal tissue to variable degree. Associated symptoms are common from 
60 years of age and some 50% of men over 80 years will have  lower urinary tract 
symptoms (LUTS) associated with BPH.  
Prevalence: 
The prevalence of clinical BPH is approximately 70% substantially greater than 
that of other common diseases such as a diabetes or asthma. 
The prevalence of BPH increase with age. 
According to the National Institutes of Health, there are more than 7.8 million 
BPH diagnoses made.   
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Histological evidence of BPH emerges after age 30, with 50% prevalence in men 
age 50-61 and 90% prevalence by age 90. However, it is difficult to predict how many of 
these cases will progress to clinical BPH. The overall prevalence of clinical BPH (BPH 
with LUTS) is 10.3%, with a maximum prevalence of 24% by age 80. It is estimated that 
45% of nonsymptomatic 46-year-old men with histological BPH will develop LUTS over 
the next 30 years.  
Causes: 
The cause of BPH is not well understood. No definite information on risk factors 
exists. 
 For centuries, it has been known that BPH occurs mainly in older men and that it 
doesn’t develop in men whose testes were removed before puberty. For this reason, some 
researchers believe that factors related to aging and the testes may spur the development 
of BPH.  
Throughout their lives, men produce testosterone, an important male hormone, and 
small amounts of estrogen, a female hormone. As men age, the amount of active 
testosterone in the blood decreases, leaving a higher proportion of estrogen.  
Studies done on animals have suggested that BPH may occur because the higher 
amount of estrogen within the gland increases the activity of substances that promote cell 
growth.  
Another theory focuses on dihydrotestosterone (DHT), a substance derived from 
testosterone in the prostate, which may help control its growth. Most animals lose their 
ability to produce DHT as they age. However, some research has indicated that even with 
a drop in the blood’s testosterone level, older men continue to produce and accumulate 
high levels of DHT in the prostate. This accumulation of DHT may encourage the growth 
of cells.  
Scientists have also noted that men who do not produce DHT do not develop BPH.  
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Some researchers suggest that BPH may develop as a result of “instructions” given 
to cells early in life. According to this theory, BPH occurs because cells in one section of 
the gland follow these instructions and “reawaken” later in life. These “reawakened” cells 
then deliver signals to other cells in the gland, instructing them to grow or making them 
more sensitive to hormones that influence growth. 
Enlargement of central part of the prostate (transition zone) narrows the calibre of 
the urethra passing through its middle and causes obstruction to the flow of urine from 
the bladder. 
Clinical features: 
The primary symptoms of BPH are due to the prostate obstructing the urethra. 
They consist of, 
• Hesistancy,  
• Poor prolonged flow  
• And a sensation of incomplete empting,  
Secondary (irritative) symptoms , 
• Comprising urinary frequency (going often),  
• Urgency of micturation(going in a hurry)  
• And urge incontinence (leaking if you can’t get to a toilet in time).  
Urge incontinence are not specific to BPH.  
Patients may present more dramatically with acute urinary retention when they are 
suddenly unable to micturate and develop a painful distended bladder. This is often 
precipitated by excessive alcohol intake, constipation or prostatic infection. It is an 
emergency and requires the bladder to be drained by catheter to receive the retention. 
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In chronic urinary retention the bladder slowly distends due to inadequate 
emptying over long period of time. This condition is characterized by pain-free bladder 
distention which may result in hydroureter, hydrinephrosis and renal failure. 
Patients with chronic retention can also develop acute retention; so called acute on 
chronic retention. They require careful management because of their renal failure. 
 In some patients, the back-pressure caused by the obstruction separates nerve 
endings from the bladder muscle fibres they are travelling towards, causing the bladder to 
behave in a reflex manner rather like a baby’s bladder does. 
           
  Other BPH symptoms relate to the stagnation of urine, which can lead to urinary 
infection (pain on and frequency of passing urine) or stone formation (recurent urinary 
infections and frequency), and the symptoms of kidney failure. 
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 Getting up at night once or twice to pass urine (‘nocturia’) becomes increasingly 
common with increasing age in both sexes as the kidneys make more urine at night. It is 
not necessarily a symptom of problems, although it can be bothersome. 
 Dribbling urine after the main stream has finished is common in middle-age and 
beyond and is also not necessarily a sign of prostate or bladder problems. It is due to 
pooling of urine in the ‘U’ bend of the urethra after it has left the bladder due to age-
related weakness of the muscle (‘bulbospongiosus’) that surrounds that part of the 
urethra. 
           This is the same muscle that contracts to expel semen out of the urethra during 
climax. The solution is either to push a finger up behind the scrotum and run it forwards 
to milk the urine out of the urethra or simply to put some toilet tissue into your 
underwear. 
Investigations: 
All patients with bothersome urinary symptoms should be investigated as the 
severity of BPH symptoms does not always reflect the severity of the problem. 
Urine sample: 
This is taken to look for the presence of blood or inflammatory cells in the urine 
and to exclude infection. 
1. Albumin 
2. Sugar 
3. Deposit 
Blood tests: 
Prostate-specific antigen (PSA): 
                             PSA is a chemical which is only produced by prostate cells and which 
is detectable in the blood. A number of factors cause its increased production:          
 1. Increasing age, 
2. Increasing prostate size,  
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3. Ejaculation,  
4. Urinary infection,  
5. Prostatitis,  
6. Prostate injury (such as a biopsy)  
7. Prostate cancer. 
 
PSA, a single chain glycoprotein with a molecular weight of 34 kilodaltons, is 
produced by all prostatic epithelial cells whether benign or malignant. Serum PSA levels 
are believed to be elevated through leakage of intraprostatic PSA into the systemic 
circulation. In the systemic circulation, PSA occurs in both a free form (free PSA) and a 
form complexed to endogenous prostate inhibitors such as alph-1-antichymotrypsin. A 
common, reliable, reproducible test that is easy to obtain in nearly any clinical setteing, 
serum PSA is the biomarker available for prostate cancer. 
 
Flow rate (FR) : 
Flow rate is a simple test performed to determine how quickly a bladder can be 
emptied and is used to quantify the presence or absence of obstruction, which may 
indicate BPH. With a comfortably-full bladder, the patient urinates into a machine which 
measures the rate of urine flow. A ‘bell’-shaped curve with a maximum flow of 15 ml/sec 
is normal. 
 
Post-void residual (PVR): 
Post-void residual test measures the amount of urine that remains in the bladder by 
means of an ultrasound scan, usually after a flow rate. Up to 100 ml is normal. 
Ultra Sonogram: 
 Estimate the dimension and volume of the prostate gland. 
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Digital Rectal Examination (DRE):  
  This examination is usually the first test done. The doctor inserts a gloved finger 
into the rectum and feels the part of the prostate next to the rectum. This examination 
gives the doctor a general idea of the size and condition of the gland. 
IPSS  (International Prostate symptoms Score): 
The IPSS is a questionnaire designed to determine the seriousness of a man's 
urinary symptoms and to help diagnose BPH. The patient answers seven questions related 
to common symptoms of BPH. How frequently the patient experiences each symptom is 
rated on a scale of 1 to 5. 
 These numbers added together provide a score that is used to evaluate the 
condition. An IPSS score of 0-7 means the condition is mild; 8-19, moderate; and 20-35, 
severe 
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International Prostate Symptom Score (IPSS) 
Name:_______________________________________ Date:___________________ 
Age: 40-49          50-59     60-69   70+ 
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Incomplete emptying 
How often have you had a 
sensation of not emptying 
your bladder completely after 
you finish urinating? 
0 1 2 3 4 5 
 
Frequency 
How often have you had to 
urinate again less than two 
hours after you finished 
urinating? 
0 1 2 3 4 5 
 
Intermittency 
How often have you found you 
stopped and started again 
several times when you 
urinated? 
0 1 2 3 4 5 
 
Urgency 
How difficult have you found it 
to postpone urination? 
0 1 2 3 4 5 
 
Weak stream 
How often have you had a 
weak urinary stream? 
0 1 2 3 4 5 
 
Straining 
How often have you had to 
push or strain to begin 
urination? 
0 1 2 3 4 5 
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Nocturia 
How many times did you 
typically get up at night to 
urinate? 
0 1 2 3 4 5 
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OTHERS: 
Cystoscopy or telescopic inspection: 
Cystoscopy inspection of the bladder is usually performed in patients with 
‘irritative’ bladder symptoms to exclude physical bladder irritants, such as a stone or 
cancer, which are unusual.  
It can be performed awake under local anaesthetic and using a flexible telescope 
or whilst asleep under general anaesthetic. 
In this examination, inserts a small tube through the opening of the urethra in the 
penis. This procedure is done after a solution numbs the inside of the penis so all 
sensation is lost. The tube, called a cystoscope, contains a lens and a light system that 
help see the inside of the urethra and the bladder. This test allows to determine the size of 
the gland and identify the location and degree of the obstruction. 
 
Urodynamic test: 
 
Urodynamic testing involves filling the bladder via a catheter inserted through the 
penis and measuring its behaviour (via a second catheter in the penis and a third in the 
rectum) as it fills and empties.  
It can be an uncomfortable and undignified test and fortunately is not often 
necessary as other methods exist to obtain the same information in most patients. 
However, then these tests are equivocal, urodynamics often provide the answer 
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Disease progress: 
 
 
 
 
 
BPH patient
Increased risk of 
progression
PSA>1.5ng/ml 
, Volume > 30cc
Pharmacotheraphy to 
arrest disease progress
Disease not likly to 
progress
PSA<1.5ng/ml, Volume 
< 30cc
Symptomatic 
Treatment
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Management: 
 
Best Foods for Prostate Health: 
 
Prostrate Health Diet 
• Vegetables from the cruciferous family (broccoli, cabbage and cauliflower) 
contain isothiocyanates, which are phytochemicals that appear to be protective. 
• Omega-3 fats seem to reduce the risk of prostate cancer, Use Fish and vegetable 
oils high in Omega-3 Fats 
• Margarine, vegetable oils, nuts and seeds, wheat germ and whole grains are  a good 
sources. Vitamin E is recognized to reduce prostate inflammation 
• Whole grains present fibre, selenium, vitamin E and phytochemicals, all of which 
play a role in the prevention of cancer. 
• Foods such as tomatoes, tomato products, red grapefruits and watermelons appear 
to reduce the risk of Prostate Cancer. Tomato-based pasta sauces and soups may 
be especially beneficial. Lycopene is fat soluble so is better absorbed when eaten 
with a little fat. 
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• Antioxidant is found in nuts especially Brazil nuts, seafood, fish, wheat bran, 
wheat germ, oats and brown rice. 
• Selenium is another mineral that may offer protection. 
• Soy products can help prevent prostate enlargement and may slow tumour growth. 
•  Red meat is high in saturated animal fats and has been linked to an increased 
incidence of prostate problems. Avoid Red Meat. 
• Obesity has also been linked to prostate troubles and cutting back on red 
meat can help you lose weight. 
• Drink plenty of fluids to flush the bladder. Caffeine, beer and spices should be 
reduced to a minimum. 
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Trial drugs 
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LITERATURE REVIEW OF TRIAL DRUGS 
 
¦ÅûÅí¸õ : 
 
Chemical Name   : Stannum (TIN)  
Í¨Å   :  ¨¸ôÒ 
 
¾ý¨Á  :  ¦ÅôÀõ 
                                                           
À¢¡¢×   :  ¸¡÷ôÒ 
 
¦ºö¨¸: 
• ¸¢ÕÁ¢¿¡º¢É¢  (Anti-dote) 
• ¾¡Ð ¦ÅôÀ¸üÈ¢ (Sedative) 
• ÐÅ÷ôÀ¢  ( Astringent) 
• Å£ì¸ÓÕì¸¢  (Deobstruent) 
 
Ì½õ   (Properties)  : 
  
¾¡¸íì ¸ÃôÀ¡ý ºÄ§Á¸õ À¢ò¾¸À 
§Á¸ ¦Á¡Ç¢Áí¸ø ¦ÅôÒÀÄõ- Á¡¸¢Ãó¾¢ 
ÐûÇ¢ÂÁóò ¾¡Ã ÍÅ¡ºÓÁó ¾¡ì¸¢É¢Ôõ 
   ¦ÅûÇ£Âõ §À¡ìÌõ Å¢¾¢. 
-À¾¡÷ò¾ Ì½ º¢ó¾¡Á½¢ 
 
• þÐ º¢ÈôÀ¡¸ ƒÉÉ, ºÄ ¯ÚôÒ¸¨Ç ÀüÈ¢Â §¿¡ö¸ÙìÌ 
ÅÆí¸ôÀÎ¸¢ÈÐ. 
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¸üÈ¡¨Æ:- 
 
Botanical Name  :  Aloe vera 
Family         :  Lilliaceae 
À.¯    : þ¨Ä º¡Ú 
Í¨Å   : º¢Ú¨¸ôÒ 
¾ý¨Á  : ¾ðÀõ 
À¢¡¢×   : þÉ¢ôÒ 
 
¦ºö¨¸: 
 ¯ÃÁ¡ì¸¢  (Tonic) 
 ¯¼ü§ÈüÈ¢  (Nutrient) 
 ¿£÷ÁÄõ§À¡ì¸¢ (purgative) 
 ÕÐ×ñ¼¡ì¸¢ (Emmenagogue) 
 
Ì½õ   (Properties) : 
 
 
¦À¡øÄ¡§Á ¸í¸ÀõÒ ØîÝ¨Ä Ìð¼Ãºõ 
«øÄ¡÷Áò ¾õÀ¸ó¾ ÃíÌýÁõ ±øÄ¡õÅ¢ð 
§¼Ì Á¡¢ìÌ ¦Á¡¢îºü ¸¢¡¢îºÃÓ 
Á¡Ì Á¡¢ìÌ ÁÕñÎ     
- §¾Ãý Ì½Å¡¸¼õ 
  
 
 
64 
   
DRUGS OF VELVANGA PARPAM 
 
 
 
 
 
 
 
 
 
                   
  
PURIFIED 
VELVANGAM 
EGG SHELL 
ALOVE VERA 
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Materials & Methods 
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METERIALS AND METHODS 
PROTOCOL 
Introduction: 
The clinical trial for benign prostate hyperplasia was decided to be conducted as 
an open label study. 
Data collection: 
• Literary evidence from various 
• Siddha books 
• Medical journals 
• Internet 
Trial spot: 
The entire study was conducted on patients on attending the OPD of Government 
Siddha Medical College, Aringnar Anna Hospital Of Indian Medicine Campus , 
Arumbakkam, Chennai- 106 , during the period 2010-2013. 
Population: 
The population consists of Benign Prostatic hyperplasia patients satisfying the 
inclusion and exclusion criteria mentioned below. 
Inclusion Criteria: 
1. Age:  between 50 - 80 years. 
2. Clinical signs and symptoms of BPH for > 1months. 
3. Willing to give specimen of blood for investigation when required. 
4. PSA Score < 4ng. 
5. Post void residual urine volume < 350cc. 
6. Willing to attend the OPD once in 7 days.  
7. Adhere to protocol requirements with written informed consent.                                                  
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Exclusion Criteria: 
1. History/ Clinical evidence of Prostate Cancer or a serum PSA > 4 ng/ml. 
2. Clinical evidence of any of the bladder or Urinary tract conditions. 
3. Post void residual urine Volume > 350 ml by ultrasound. 
4. Patient who have participated in a drug study in past 3 months.   
                                                                          
Duration of Treatment: 
 30 days. 
 
Patients were followed under the guidance and supervision of the HOD, Professor, 
Reader, Lecturer and Asst. Lecturer of the Maruthuvam P.G Department, GSMC, 
Chennai-106. 
 
20 patients were selected and carefully studied for their history, clinical 
examinations, investigations and management. 
 
Evaluation of Clinical Parameters: 
 
The history includes past, personal, family, occupation, dietary habits, Seasonal 
history, and associated history. 
 
Investigations: 
 
 Blood 
 TC, 
 DC,  
 ESR,  
 HB,  
 Blood sugar, 
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 Blood Urea  
 Serum Cholesterol  
 Serum Creatinine 
 
 Prostate Specific Antigen (PSA) 
 
 Urine:     
        
 Albumin 
 Sugar 
 Deposit  
 USG – KUB: 
o Prostate 
• Measurement 
• Volume  
• Post void residual urine 
Investigations Based On Siddha System: 
1. Envagai Thervu:        
Na, Niram, Mozhi, Vizhi, Sparisam, Naadi, Malam,  Moothiram 
2. Neerkuri: 
Niram, Manam, Eadai, Nurai, Enjal 
3. Neikuri :  
      
A case sheet format was prepared on the basis of the Siddha methodology example 
envagai thervvugal, mukkutram, nilam, kaalam, udal thathugal, including neerkuri 
and neikuri. Individual case sheet was maintained for each patient at outpatient 
department. 
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TRIAL DRUG: 
Drug:  
 Velvanga Parpam: 
Reference:  
Veeramamunivar vagada thirattu  
  
Ingredients: 
1. Velvangam (Tin) – 100gm 
2. Egg shell – 100gm 
3. Aloe vera juice 
Procedure: 
¦ºùÅ¢¾¡õ ¦ÅûÅí¸ï ¦ºôÒõ ÀÄÁ¢ÃñÎ 
ºùÅ¸ýÈ Ä½¼ò§¾¡ Ã¡ÉÐÅ¡õ- þùÅ¾¨Éì 
¸øÅò¾¢ð Îô¦À¡ÊòÐì ¸¡Ï¸Õõ ¦À¡ü¸Äò¾¢ø 
¦ÅûÅí¸õ §À¡ð¼ÎôÀ¢ý Á£Ð. 
 
²üÈ¢ò ¾ÆÄ¢ð ¦¼¡¢ò¾ñ¼ò Ðûº¢Ú¸ô 
§À¡ðÎò§¾ öô À¡ö¸¡¢Â ¦À¡üÚÎôÀ¡ø- º¡üÚàû 
¦ºýÈÀ¢ýÒ ¿£À¡÷ì¸Š ¦º÷ó¾Åí¸õ ÀüÀÁ¡õ 
´ýÚ¸Õô À¡Â¢ÕìÌ §Á¡÷ 
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Á£ñÎí¸ø Åò¾¢Ä¢ðÎ ¦ÁîÍÌÁ ¡¢îº¡üÈ¢ü 
âñ¼¿¡ü º¡Áõ Ò¸úó¾¨ÃòÐ- §ÅñÎõÅ¢ø¨Ä 
¬ì¸¢ ÔÄ÷ò¾¢ ÂÆÌ¦ÀÈ §Å¡ðÊÄ¢ðÎô 
§À¡ì¸¢ø ¸Åºõ Ò¡¢ 
 
À¸÷ó¾¸Å ºò¨¾ô ÀýÉ¢ÃñÎÅ£¨º 
Ô¸ó¾ ÅÈðÊÂ¢ü¸¡ü§È¡¼ - ¿¢¸úó¾Ò¼õ 
§À¡ð¦¼Îì¸Å¡½Ãò¨¾ô §À¡ýÈ ¿¢ÈôÀüÀÁ¡õ 
°ð¼Ç× ÌýÈ¢Â¨Ã ¦Â¡ýÚ 
 
º¡üÚÍ¸ ¿£÷ô¦ÀÕìÌó ¾¡¾¢ý º¢Ã¡Å¸Óõ 
§¾¡üÈ¢Â¿£÷ô ¨ÀÂ¢ýÉÐ Ð÷ÀÄÓõ- §¸ð¨¼ÔÚõ 
§¾¸ÀÄó ¾¡ÐÒ‰Ê §ºÕ¦Á¡Õ ¾£í¸¢ø¨Ä¦Âý 
Å¡¸¼ò¾¢ §ÄÔÚ¾¢ ¨Å. 
-Å£ÃÁ¡ÓÉ¢Å÷ Å¡¸¼ ¾¢ÃðÎ -72 
 
Purified velvangam is taken in a iron bowl and purified powder of egg shell is 
poured on the melted velvangam and stir it thoroughly until the velvangam completely 
merge. Add juice of aloe vera and grind it for 12 hours(4 samam) and keep it in pudam.  
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Dosage:   
65 mg  
Adjuvant:   
Honey / butter. 
Duration:   
30 days  
Indication: 
• Normal urine flow 
• Urinary Bladder disease. 
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DRUG 
 
 
 
 
 
 
 
 
 
 
 
  
VELVANGA PARPAM 
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Results & Observations 
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RESULTS AND OBSERVATIONS 
 
The factors considered for the purpose of the study comprised of the following: 
 
 Age Distribution 
 Thinai 
 Paruvakaalam 
 Occupational status 
 Socio economic Status 
 Food habits 
 Personal habits 
 Symptoms 
 Classifications of results according to Vali, Azhal & Iyyam 
 Udal kattugal 
 Enn vagai thervu 
 Naadi 
 Classification on the basis of Neikuri 
 Clinical progress 
 Results after treatment.  
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AGE DISTRIBUTION: 
SL.NO AGE NO. OF PATIENTS /20 PERCENTAGE 
1. 51-60 6 30% 
2. 61-70 8 40% 
3. 71-80 6 30% 
 
     
 
Inference: 
According to the above mentioned data 40% of patients were in age groups 
61-70 years, 30% of patients were in age group 71-80 year,30% of patients were in 
age group 51-60 years. 
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THINAI: 
 
SL.NO THINAI NO. OF PATIENTS /20 PERCENTAGE 
1. Kurinji 3 15% 
2. Mullai 0 0% 
3. Marutham 0 0% 
4. Neithal 17 85% 
5. Paalai 0 0% 
 
 
 
 
 
Inference: 
 
From the above data 85% of patient from Neithal and15% of cases from Kurinji. 
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PARUVAKAALAM: 
 
SL.NO PARUVAKAALAM MONTH 
NO. OF 
PATIENTS 
/20 
PERCENTAGE 
1. Kaar Kaalam 
Avani, Puratasi, 
Mid Aug-Mid Oct 7 35% 
2. Kuthir Kaalam 
Iyppasi, Kaarthigai 
Mid Oct-Mid Dec 2 10% 
3. Munpani Kaalam 
Margazhi, Thai 
Mid Dec-Mid Feb 1 5% 
4. Pinpani Kaalam 
Maasi, Panguni 
Mid Feb-Mid April 6 30% 
5. Elavenil Kaalam 
Chithirai, vaigasi 
Mid April- MidJune 0 0% 
6. Muthuvenil Kaalam 
Aani, Aadi 
Mid June-Mid Aug 4 20% 
 
         
Inference: 
      35% of case came in Kaar kaalam and 30% of case in Pinpani kaalam, 20% of 
cases in Muthuvenil kaalam, 10% of cases in Kuthir kaalam and 5% of cases in Munpani 
kaalam.  
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OCCUPATIONAL STATUS: 
 
 
 
 
 
 
 
 
 
 
  
    
 
 
Inference: 
25% of cases were Professionals. 
75% of cases were Retired persons. 
 
Professionals
25%
Nil
75%
OCCUPATION
SL.NO OCCUPATION NO OF PATIENT /20 PERCENTAGE 
1. Professionals 5 25% 
2. Retired persons 15 75% 
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SOCIO ECONOMIC STATUS: 
 
Sl.No. Socio Economic Status No.of Patients /20 Percentage 
1. Low income group (below 10000/month) 7 35% 
2. Middle income group (10000-20000/ month) 11 55% 
3. High income group (above 20000/month) 2 10% 
 
  
         
 
Inference: 
55% of cases belong to middle income group and 35% of patients belong to lower 
income group. 10% of cases belong to high income group.  
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FOOD HABITS: 
 
SL.NO. FOOD HABIT NO. OF PATIENT / 20 PERCENTAGE 
1. Vegetarian 2 10% 
2. Mixed diet including Non-vegetarian 18 90% 
 
 
    
 
Inference: 
90% of cases were mixed diet including Non- vegetarian. 
10% of cases were Vegetarian.  
Vegitarian
10%
Mixed diet
90%
Food Habit
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PERSONAL HABIT: 
 
 
SL.NO. PERSONAL HABIT NO. OF PATIENT / 20 PERCENTAGE 
1. Smoker 5 25% 
2. Alcoholic 2 10% 
3. Tobacco chewing 0 0% 
4. Others 13 65% 
 
 
 
 
  
 
Inference: 
65% of patients had no bad habits, 25% of cases were smoker and 10% of cases 
were alcoholic, 0% of cases were Tobacco Chewing. 
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SYMPTOMS: 
SL.NO SYMPTOMS NO. OF PATIENTS/ 20 PERCENTAGE 
1. Incomplete emptying 13 65% 
2. Frequency of urine 14 70% 
3. Intermittency of urine 14 70% 
4. Urgency 15 75% 
5. Weak stream 15 75% 
6. Straining 9 45% 
7. Nocturia 16 80% 
 
 
Inference: 
             65% of cases had Incomplete emptying, 70% of cases had Frequency of urine, 
70% of cases had Intermittency of urine, 75% of cases had Urgency, 75% of cases had 
Weak stream, 45% of cases had Straining, 80% of cases had Nocturia. 
. 
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VATHAM: 
 
SL.NO. VATHAM NO. OF PATIENT / 20 PERCENTAGE 
1. Pranan 0 0% 
2. Abanan 20 100% 
3. Viyanan 20 100% 
4. Uthanan 2 10% 
5. Samanan 0 0% 
6. Nagan 0 0% 
7. Koorman 9 45% 
8. Kirugaran 2 10% 
9. Devathathan 20 100% 
10. Thananjeyan 0 0% 
 
    
Inference: 
Abaanan, viyanan, devathathan were affected in 100% of patients, Koorman was 
affected in 45% of patients anduthanan and kirugaran were affected in 10% of patients.  
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PITHAM: 
 
SL.NO. PITHAM NO.OF PATIENT /20  PERCENTAGE 
1. Anar pitham 0 0% 
2. Ranjagam 0 0% 
3. Saathagam 20 100% 
4. Prasagam 0 0% 
5. Alosagam 9 45% 
 
 
 
 
Inference: 
Sathagam was affected in 100% of cases, Alosagam was affected in 45% of 
patients. 
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KAPAM: 
 
 
 
 
 
Inference: 
Santhigam was affected in 85% of patients. 
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SL.NO. KAPAM NO. OF PATEINTS /20 PERCENTAGE 
1. Avalambagam 0 0% 
2. Kilethagam 0 0% 
3. Pothagam 0 0% 
4. Tharpagam 0 0% 
5. Santhigam 17 85% 
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UDAL KATTUGAL: 
 
SL.NO. UDAL KATTUGAL NO. OF PATIENT / 20 PERCENTAGE 
1. Saaram 20 100% 
2. Seneer 0 0% 
3. Oon 20 100% 
4. Kozhuppu 0 0% 
5. Enbu 17 85% 
6. Moolai 0 0% 
7. Sukkilam 0 0% 
 
 
 
 
 
Inference: 
Both Saaram and Oon were affected in 100% of patients and Enbu was affected in 
85% of patients. 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
100%
0%
100%
0%
85%
0% 0%
Udal Kattugal
87 
   
ENVAGAI THERVUGAL: 
 
 
SL.NO. ENVAGAI THERVUGAL NO. OF PATIENT / 20 PERCENTAGE 
1. Naa 0 0% 
2. Niram 0 0% 
3. Mozhi 0 0% 
4. Vizhi 9 45% 
5. Naadi  20 100% 
6. Sparisam 1 5% 
7. Malam 7 35% 
8. Moothiram 20 100% 
 
 
 
Inference: 
Naadi  and moothiram were affected in 100% of patients and 45% of patients vizhi 
was affected, 35% of patients Malam was affected, 5% of patients sparisam was affected. 
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NAADI: 
 
SL.NO. NAADI NO. OF PATIENT / 20 PERCENTAGE 
1. Kappa Pitham 0 0% 
2. Vaatha Pitham 15 75% 
3. Pitha Vaatham 5 25% 
4. Vaatha Kapam 0 0% 
5. Kapa Vaatham 0 0% 
 
 
 
Inference: 
75% of patient’s vatha pitham naadi was felt and 25% of cases pitha vatha naadi was felt.  
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NEIKURI: 
 
SL.NO. NEIKURI NO. OF PATIENT / 20 PERCENTAGE 
1. Vatham  (Spreads like Snake) 11 55% 
2. Pitham (Spreads like Ring) 2 10% 
3. Kapam  (Stands like Pearl) 7 35% 
 
 
 
 
Inference: 
55% of cases show Vatha neikuri, 35% shows Kapha neikuri and 10% shows 
Azhal neikuri. 
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CLINICAL PROGRESS: 
SL.NO SYMPTOMS 
NO. OF PATIENTS/ 20 PERCENTAGE 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
1. Incomplete emptying 13 2 65% 10% 
2. Frequency of urine 14 6 70% 30% 
3. Intermittency of urine 14 5 70% 25% 
4. Urgency 15 7 75% 35% 
5. Weak stream 15 7 75% 35% 
6. Straining 9 0 45% 0% 
7. Nocturia 16 2 80% 10% 
 
 
Inference 
Before treatment 65% of cases had Incomplete emptying, 70% of cases had 
Frequency of urine, 70% of cases had Intermittency of urine, 75% of cases had Urgency, 
75% of cases had Weak stream, 45% of cases had Straining, 80% of cases had Nocturia. 
After treatment Straining were completely relieved and Nocturia and Incomplete 
emptying 10% and 25% of cases Intermittency of urine.  
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IPSS PROGRESS: 
 
SL.NO IPSS 
NO OF PATIENTS / 
20 PERCENAGE 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
1. Mild ( 0- 7 ) 2 9 10% 45% 
2. Moderate ( 8 – 19 ) 14 9 70% 45% 
3. Severe ( 20 – 35 ) 4 2 20% 10% 
 
 
 
 
Inference: 
 Before treatment 10% of cases had Mild symptoms, 70% of cases had Moderate 
symptoms, 20% of cases had severe symptoms. After treatment,45% of cases come to 
Mild Symptom category 45% of cases  come under moderate category, and 10% of cases 
come under severe category.  
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GRADATION OF RESULTS: 
SL.NO. Results NO. OF PATIENT / 20 PERCENTAGE 
1. Good improvement 11 55% 
2. Moderate Improvement 6 30% 
3. Poor Improvement 3 15% 
 
 
         
 
 
Inference: 
55% of Patients show good improvement, 30% of shows moderate improvement 
and 15% of cases shows poor improvement. 
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LABORATORY INVESTIGATION REPORT (OP) 
 
 
 
 
TC – Total Count        Hb – Haemoglobin       OEC – Occasional Epithelial Cells 
Dc – Differential Count               ESR – Erythrocyte Sedimentation Rate     OPC – Occasional Pus Cells 
P – Polymorph        Alb – Albumin       FPC – Few Pus Cells 
L – Lymphocyte        Sug – Sugar        FEC – Few Epithelial Cells 
  E – Eosinophil        Dep – Deposits 
 
SL. 
NO. 
OP. NO.              
 
NAME 
 
AGE 
 
HEAMOTOLOGICAL REPORT 
URINE ANALYSIS STOOL  EXAMINATION 
BEFORE TREATMENT AFTER TREATMENT ESR(mm) HB(Gm) 
TC 
(Cu/mm) 
DC 
TC 
(Cu/mm) 
DC BT AT 
BT AT 
BT AT BT AT 
P L E P L E ½ Hr 1 Hr ½ Hr 1 Hr Alb Sug Dep Alb Sug Dep Ova Cyst Ova Cyst 
1. 3619 Mr.Sheshatri 56 11,000 55 42 3 10,600 60 36 3 15 25 10 13 13.2 13 Nil Nil OEC Nil Nil Nil Nil Nil Nil Nil 
2. 7740 Mr.Gangatharan 64 9,800 56 38 6 9,800 60 34 8 15 30 12 18 15 14.5 Nil Nil OEC Nil Nil OPC Nil Nil Nil Nil 
3. 8494 Mr.Balakrishnan 72 10,400 58 39 3 11,000 58 40 4 5 22 4 10 12.2 12.5 Nil Nil OEC Nil Nil OPC Nil Nil Nil Nil 
4. 2179 Mr.Nadesan 74 11,000 59 37 4 10,500 55 42 5 5 10 8 16 12.4 12.5 Nil Nil FEC Nil Nil Nil Nil Nil Nil Nil 
5. 636 Mr.Thiruvengadam 68 9,700 58 36 6 9,800 56 40 2 3 5 4 8 12 12 Nil Nil FEC Nil Nil Nil Nil Nil Nil Nil 
6. 3155 Mr.Rangarajan 61    11,300 55 35 6 11,400 60 35 3 7 12 10 14 13 12.5 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
7. 5269 Mr.Ramasamy 75 11,600 56 35 4 10,100 62 34 4 3 5 4 10 13 12.8 Nil Nil FPC Nil Nil Nil Nil Nil Nil Nil 
8. 9954 Mr.Ganesan 58 10,100 62 34 4 10,000 62 28 4 11 32 6 10 12 13 Nil Nil FEC Nil Nil OPC Nil Nil Nil Nil 
9. 2129 Mr.Kannan 62 9,600 59 35 6 9,500 58 30 3 3 7 3 6 15 15 Nil Nil FEC Nil Nil Nil Nil Nil Nil Nil 
10. 5782 Mr.Gopikrishnan 54 9,900 60 37 4 9,800 55 35 6 10 20 9 18 13.8 13.7 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
11. 4592 Mr.Sanmugam 75 9,700 55 32 5 10,000 56 35 4 2 4 3 6 14.8 15 Nil Nil FPC Nil Nil Nil Nil Nil Nil Nil 
12. 1647 Mr.Jeganathan 55 9,800 57 28 3 10,100 58 34 5 6 10 5 12 14.6 14.6 Nil Nil FPC Nil Nil Nil Nil Nil Nil Nil 
13. 695 Mr.Govindaraj 62 9,700 58 35 7 9,800 65 40 6 11 20 7 12 11 12 Nil Nil OEC Nil Nil Nil Nil Nil Nil Nil 
14. 1799 Mr.Jeyaraman 75 11000 58 37 2 10,400 55 32 5 2 5 4 10 13 12.8 Nil Nil FEC Nil Nil Nil Nil Nil Nil Nil 
15. 2193 Mr.Francis 68 10,800 66 30 4 10,700 55 36 3 2 5 3 6 14 14.2 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
16. 189 Mr.Ramachandran 77 9700 57 38 5 10,700 60 37 4 3 5 3 8 12.8 13 Nil Nil FPC Nil Nil Nil Nil Nil Nil Nil 
17. 9445 Mr.Krishnan 65 11,800 58 38 4 9,800 55 32 5 2 5 4 10 13 12.8 Nil Nil Nil Nil Nil OPC Nil Nil Nil Nil 
18. 716 Mr.Kumaresan 57 10,800  60 32 8 9,600 60 38 2 10 22 9 18 12.4 12.5 Nil Nil FEC Nil Nil OPC Nil Nil Nil Nil 
19. 7052 Mr.Nadarajan 60 10,100 54 42 4 11,200 55 30 4 7 17 8 18 14 14.1 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
20. 6412 Mr.Guberan 68 9,900 59 37 4 10,800 60 35 6 12 24 10 15 13 13 Nil Nil FEC Nil Nil FPC Nil Nil Nil Nil 
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NO. OF PATIENTS – BEFORE TREATMENT AND AFTER TREATMENT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               PRU – Post Void Residual Urine 
SL.NO. OP. NO NAME AGE 
SCREENING TEST 
(Serum total PSA        
ng/ml) 
USG PELVIS -  PROSTATE 
NO. OF DAYS RESULT BEFORE TREATMENT AFTER TREATMENT 
Measurement 
(cm) 
Volume (cc) PRU (ml) 
Measurement 
(cm) 
Volume (cc) PRU(ml) 
1. 3619 Mr.Sheshatri 56 0.50 3.8*3.2*3.1 20 43 3.8*3.0*3 20 18 30 Good  
2. 7740 Mr.Gangatharan 64 1.85 5.2*5.8*5.2 84 38 5.6*5.1*4.9 78 80 45 Good     
3. 8494 Mr.Balakrishnan 72 0.72 4.5*4.6*3.2 30 54 4.5*5.0*3 30 50 45 Poor 
4. 2179 Mr.Nadesan 74 2.03 3.6*4.6*4.7 45 60 3.5*4.2*4.0 45 51 30 Moderate 
5. 636 Mr.Thiruvengadam 68 1.85 3.8*4.2*3.7 29 28 3.2*4*3.1 27 9 30 Good 
6. 3155 Mr.Rangarajan 61 0.23 4.9*3.7*3.4 32 15 4.8*3.5*4.0 30 7 30 Moderate 
7. 5269 Mr.Ramasamy 75 0.95 4.6*3.8*3.3 30 40 4.7*3.2*3 28 35 45 Moderate 
8. 9954 Mr.Ganesan 58 3.00 3.8*4.2*3.7 45 100 3.9*4*3.1 38 95 30 Moderate 
9. 2129 Mr.Kannan 62 0.925 4.3*3.5*2.9 23 96 4.3*4.1*2.5 25 100 45 Poor 
10. 5782 Mr.Gopikrishnan 54 1.45 5*3.5*3 28.5 164 4.1*3.2*2.8 25 125 45 Good 
11. 4592 Mr.Sanmugam 75 2.52 4.3*4.3*3.5 33.7 85 4.1*4.0*3.2 20 72 45 Good 
12. 1647 Mr.Jeganathan 55 0.69 4.2*3.6*3.5 28 96 4.0*3.6*3.2 15 25 30 Good 
13. 695 Mr.Govindaraj 62 2.56 4.5*5.1*4.7 56.7 250 4.2*4.0*3.8 34 40 45 Good 
14. 1799 Mr.Jeyaraman 75 0.90 4.4*4.5*4.6 47 100 4.4*4.5*3.8 23.5 110 30 Moderate 
15. 2193 Mr.Francis 68 0.82 5.6*7.2*5.8 45 150 5.5*6.9*5 41 75 45 Good 
16. 189 Mr.Ramachandran 77 2.30 4.5*4.2*3.2 32.95 94 4.5*3.3*2.8 30 70 45 Good 
17. 9445 Mr.Krishnan 65 1.53 3.6*4.6*4.6 42 6 3.1*4.1*4.6          40 8 45 Moderate 
18. 716 Mr.Kumaresan 57 3.02 5.7*3.6*4.4 47 140 5.1*4.2*4.3 35.5 80 30 Good 
19. 7052 Mr.Nadarajan 60 0.86 4.8*3.7*4.3 32 65 4.9*4.1*5 35 118 45 Poor 
20. 6412 Mr.Guberan 68 2.98 4.9*4.4*4.1 47 120 4.2*4.0*3.8 33.7 92 30 Good 
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NO. OF PATIENTS – BEFORE TREATMENT AND AFTER TREATMENT 
 
 
IPSS – International Prostate Symptoms Score 
0-7  :  Mildly Symptomatic 
8-19  :  Moderately Symptomatic 
20-35  :  Severely Symptomatic 
 
SL.NO. 
OP. 
NO 
NAME AGE 
IPSS (TOTAL) 
Result Before 
Treatment 
After 
Treatment 
1. 3619 Mr.Sheshatri 56 7 5 Good  
2. 7740 Mr.Gangatharan 64 19 12 Good     
3. 8494 Mr.Balakrishnan 72 32 28 Poor 
4. 2179 Mr.Nadesan 74 18 10 Moderate 
5. 636 Mr.Thiruvengadam 68 17 7 Good 
6. 3155 Mr.Rangarajan 61 17 12 Moderate 
7. 5269 Mr.Ramasamy 75 15 7 Moderate 
8. 9954 Mr.Ganesan 58 11 6 Moderate 
9. 2129 Mr.Kannan 62 19 13 Poor 
10. 5782 Mr.Gopikrishnan 54 14 7 Good 
11. 4592 Mr.Sanmugam 75 13 6 Good 
12. 1647 Mr.Jeganathan 55 7 4 Good 
13. 695 Mr.Govindaraj 62 28 12 Good 
14. 1799 Mr.Jeyaraman 75 24 16 Moderate 
15. 2193 Mr.Francis 68 16 9 Good 
16. 189 Mr.Ramachandran 77 16 8 Good 
17. 9445 Mr.Krishnan 65 13 8 Moderate 
18. 716 Mr.Kumaresan 57 10 5 Good 
19. 7052 Mr.Nadarajan 60 27 24 Poor 
20. 6412 Mr.Guberan 68 14 7 Good 
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Discussion 
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DISCUSSION 
 
Benign prostatic hyperplasia is the common geriatric disease in the world wide. 
Even though the BPH is not a major disease in elderly people. When it occurring at old 
age it becomes a severe illness.BPH event is increased over the age of 50 and it produces 
the lower urinary tract obstruction which leads to following symptoms are, Incomplete 
emptying, Frequency of urine, Intermittency of urine, Urgency, Weak stream, Straining, 
Nocturia. 
Before this illness starts or aggravates the awareness about the BPH is important. 
So as to prevent the severity, and avoid these symptoms which leads to carcinoma of 
prostate.  
20 patients were treated in outpatient department of Post graduate 
pothumaruthuvam, Govt Siddha Medical College Hospital, Chennai – 106. 
All patients were subjected to preliminary investigations which include 
haematological, urine examination, USG pelvis are noted before and after Treatment 
The Trial Medicine Velvanga parpam, dose 65mg was administered twice daily 
for 30 days. 
Age Distribution: 
According to the above mentioned data 40% of patients were in age groups 61-70 
years, 30% of patients were in age group 71-80 year, 30% of patients were in age group 
51-60 years. 
. 
Distribution of Thinai: 
From the above data 85% of patient from Neithal and15% of cases from Kurinji. 
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Paruvakalam: 
According to this study 35% of case came in Kaar kaalam and 30% of case in 
Pinpani kaalam, 20% of cases in Muthuvenil kaalam, 10% of cases in Kuthir kaalam and 
5% of cases in Munpani kaalam. 
Occupational Status: 
In my study ,25% of cases were Professionals, 75% of cases were Retired persons. 
 
Socio Economic Status: 
According to this study, 55% of cases belong to middle income group and 35% of 
patients belong to lower income group. 10% of cases belong to high income group. 
Food Habits: 
According to this study , 90% of cases were mixed diet including Non-vegetarian, 
10% of cases were Vegetarian. 
 
Personal Habits: 
In my study 65% of patients had no bad habits, 25% of cases were smoker and 
10% of cases were alcoholic, 0% of cases were Tobacco Chewing.. 
Symptoms: 
            According to this study 65% of cases had Incomplete emptying, 70% of cases had 
Frequency of urine, 70% of cases had Intermittency of urine, 75% of cases had 
Urgency,75% of cases had Weak stream, 45% of cases had Straining, 80% of cases had 
Nocturia. 
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Classification of Results According To Vali, Azhal, Iyyam 
 
Vali : 
Incomplete emptying, Frequency of urine, Intermittency of urine, Urgency, Weak 
stream, Straining, Nocturia are due to deranged Abana Vayu. And Abaanan was affected 
in 100% of patients, Koorman was affected in 45% of patients, Kirugaran was affected 
10% of patients and Viyanan, Devathathan was affected in 100% of patients. 
Azhal: 
Satham was affected in100% of patients, Alosagam was affected in 45% of 
patients. 
Iyyam: 
Santhigam was affected in 85% of patients. 
Udhal Kattugal: 
Both Saaram and Oon were affected in 100% of patients and Enbu was affected in 
85% of patients 
Envagai Thervu: 
Naadi and Moothiram were affected in 100% of patients and 45% of patients vizhi 
was affected, 35% of patients Malam was affected, 5% of patients sparisam was affected. 
 Naadi: 
75% of patient’s vatha pitham naadi was felt and 25% of cases pitha vatha naadi 
was felt.. 
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Neikuri 
55% of cases show Vatha neikuri, 35% shows Kapha neikuri and 10% shows 
Azhal neikuri. 
 
Clinical Progress: 
Before treatment 65% of cases had incomplete emptying, 70% of cases had 
Frequency of urine, 70% of cases had Intermittency of urine, 75% of cases had Urgency, 
75% of cases had Weak stream, 45% of cases had Straining, 80% of cases had Nocturia. 
After treatment Straining were completely relieved and Nocturia and Incomplete 
emptying 10% and 25% of cases Intermittency of urine. 
 
IPSS progress: 
Before treatment 10% of cases had Mild symptoms, 70% of cases had Moderate 
symptoms, 20% of cases had severe symptoms. After treatment,45% of cases come to 
Mild Symptom category 45% of cases  come under moderate category, and 10% of cases 
come under severe category. 
 
Trial Medicine: 
All the 20 patients treated with the Trial Medicine Velvanga parpam with Butter 
for 15 to 30 days The disease and treatment are based primarily on the derangement of 
Mukkutram, which again is based on the Pancha bootham theory.  
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Mukkutra theory: 
 Ukkara soolai is caused by the derangement of Vatha kutram. That is, 
                   ‘neLthj rhHgJTkpd!wp !#iy tuhJ” 
And the trial drug Velvanga parpam has follows, 
S. No Content  Suvai Bootha serkai 
1. Velvangam  Kaippu Vali + Vin 
2. Alove vera Siru kaippu Vali + Vin 
 
The predominant Bootham present in Velvanga parpam is Vali (vatham). 
              Predominant suvai present in Velvanga parpam is KAIPPU, And predominant 
bootham is Vali (Katru).Hence all the content of trial drug has vali in the pancha bootha 
theory. So being the vatha disease, all the drugs having the vatha(vali) pootha treat the 
disease in OPPURAI MARUTHUVAM. 
Bio chemical analysis: 
        The result of Bio-chemical analysis reveals that Velvanga parpam contains Acid 
radicals such as a Chloride, Zinc, Calcium and Magnesium. 
Pharmacological study: 
Pharmacological study reveals that Velvanga parpam contains Anti-tumour 
activity The antitumor effect of the drug is evident from the increase in lifespan, 
reduction in solid tumour volume and also the reversal of altered haematological 
parameter almost equal to normal .The drug can be used as a novel potential agent in the 
area of tumour chemotherapy. 
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 Bio-statistical report: 
       The Bio-statistical report reveals that the result of the treatment shows 
significant result P value <0.01 ,  Before and After treatment Mean value for IPSS 
(International Prostate Symptoms Score) -6.55±3.02.  
   The above outcomes obtained from the clinical study were better and much 
encouraging. 
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Summary 
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SUMMARY 
 
The aim of the study is to reduce the symptoms of Ukkara soolai patients. The trial 
medicine Velvanga parpam was prepared as per literature. The duration of the trial period 
is 30 days. The trial dose is Velvanga parpam 65 mg twice daily with butter. I had 
selected 20 patients for the trial based on Inclusion and Exclusion criteria. 
Before treatment routine blood, urine, PSA and USG-Pelvis taken in all 20 
patients. Siddha parameters like udal thathukkal, Envagai thervu, Neerkuri and Neikuri 
were noted in case sheet proforma. Patients were instructed to come for next review once 
in 7 days. 
Patients were come with clinical symptoms like Incomplete emptying, Frequency 
of urine, Intermittency of urine, Urgency, Weak stream, Straining, Nocturia. The entire 
details of the patients were noted in the case sheet proforma. 
Age : 
Most of the patients were in the age group between 61-70 years. 
Thinai : 
Most of the patients were from Neithal Thinai 85%. 
Kalam : 
Most of the patients were affecting in Karkaalam and pinpanikaalam. 
Diet & Personal habits: 
People with habit of taking Vegetarian and Mixed Diet. 
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Mukkutrum: 
In vali abanan,viyanan, devathathan and koorman, in azhal sathagam and 
alosagam and in iyyam santhigam were affected in most of the cases. 
Udal Thathugal: 
Saaram and oon were affected in all the patients. 
Envagai Thervu: 
 Naadi and Moothiram were affected most of the patients. 
Naadi : 
Vatha pitha naadi was most common naadi felt. 
Results after treatment: 
55% of patients show good improvements, 30% of patients shows moderate 
improvement and in 15% of patients poor improvement was observed. 
Pharmacological study reveals that Velvanga parpam contains Anti-tumour 
activity The antitumor effect of the drug is evident from the reduction in solid tumour 
volume and also the reversal of altered haematological parameter almost equal to normal. 
The drug can be used as a novel potential agent in the area of tumour chemotherapy. 
 The toxicity study revealed that there were no toxic effect was observed upto 
5mg/kg of Velvanga Parpam on oral route over a period of 28 days. 
 The bio-statistical report of the clinical trial shows significant result. 
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Conclusion 
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CONCLUSION 
 Ukkara soolai (Benign prostatic hyperplasia) is primarily due to the derangement 
of vatham. 
 
 The trial medicine velvanga parpam predominating with Kaippu taste respectively 
Equivalent the vatham. 
 
 From the pre clinical pharmacological studies it is evident that the medicines were 
significant Anti-tumour activity. 
 
 The velvanga parpam did not produce any toxicity in lower dose in preclinical 
study. So it is safe drug for ukkara soolai (benign tumour). 
 
 From the preclinical study of Velvanga parpam is reduction in solid tumour 
volume. 
 
 In Bio-chemical analysis the trial medicine contains zinc and chloride. These are 
very essential for maintaining the prostate health. 
 
 No contra indication was reported during the course of the treatment. 
 
 The trial medicines gave maximum relief from the symptoms of Ukkara soolai. 
 
 Therefore the authour concluded that the trial medicine velvanga parpam should 
be a very positive remedy for Ukkara soolai (BPH).  
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ANNEXURE-I 
 
BIO-CHEMICAL ANALYSIS OF TRIAL MEDICINE 
 
 
Preparation of Sodium Carbonate extract:   
    
  2 gm of the sample drug is mixed  5 gm of Sodium carbonate and taken in a 
100 ml beaker and 20 ml of distilled water is added.  The solution is boiled for 10 
minutes, cooled and then filtered.  The filtrate is called sodium carbonate extract. 
 
S.No. 
 
Experiment 
 
Observation  
 
Inference 
1 Test for Acid Radicals   
a. Test for Sulphate 
2 ml of the above prepared extract 
is taken in a test tube.  To this add 
2ml of 4% Ammonium oxalate 
solution. 
Absence of              
White  Precipitate 
 
Absent 
b. 2ml of extract is added with 2ml 
of dilute hydrochloric acid until 
the effervescence ceases off.  Then 
2ml barium chloride solution is 
added. 
Absence of              
White  Precipitate 
 
Absent 
2. Test for Chloride: 
2ml of extract is added with dilute 
nitric acid till the effervescence 
ceases.  Then 2ml of silver nitrate 
solution is added. 
 
white precipitate 
obtained 
 
Present 
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3. Test for Phosphate 
2ml of the extract is treated 
with 2 ml of Ammonium 
molybdate  solution and 2ml of 
concentrated nitric acid. 
Absence of 
Yellow Precipitate 
 
Absent 
4. Test for Carbonate: 
2ml of the extract is treated 
with 2ml of magnesium 
sulphate solution. 
Absence of white 
precipitate 
 
Absent 
5. Test for Sulphide: 
1 gm of the substance is treated 
with 2ml of concentrated 
Hydrochloric acid 
Absence of Rotten 
egg smelling 
 
Absent 
6. Test for Nitrate: 
1gm of the substance is heated 
with copper turnings and 
concentrated sulphuric acid 
and viewed the test tube 
vertically down. 
Absence of reddish 
brown gas. 
 
Absent 
7. 
a. 
Test for Fluoride and oxalate 
2ml of the extract is added with 
2ml of dilute acetic acid and 
2ml of calcium chloride 
solution and heated.  
Absence of white 
precipitate 
 
Absent 
b. 5 drops of clear solution is 
added with 2ml of dilute 
sulphuric acid and slightly 
warmed to this, 1 ml of dilute 
potassium permanganate 
solution is added.  
Absence of KMNO4 
solution 
discolourisation. 
Absent 
8. Test for Nitrite 
3 drops of the extract is placed 
on a filter paper.  On that, 2 
drops a Acetic Acid and 2 
drops of Benzidine solution is 
placed. 
 
Absence of 
yellowish red colour 
 
Absent 
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9. Test for Borate 
2 pinches of the substance is 
made into paste by using 
Sulphuric acid and Alcohol 
(95%) and introduced into the 
blue flame. 
Absence of Green 
tinged flame 
 
Absent 
II. TEST FOR BASIC RADICALS  
10. Test for lead 
2 ml of the extract is added 
with 2 ml of Potassium iodide 
solution 
Absence of Yellow 
precipitate 
 
Absent 
11a Test for Copper 
One pinch of substance is 
made into paste with 
concentrated Hydrochloric acid 
in a watch glass and introduced 
into the non luminous part of 
the flame. 
Absence of Bluish 
green coloured 
flame. 
 
Absent 
b. 2ml of the extract is added with 
excess of Ammonia solution 
Absence of deep 
blue 
Absent 
12. Test for Aluminium 
To the 2 ml of extract.  Sodium 
Hydroxide solution is added in 
drops to excess. 
Absence of   White 
precipitate. 
Absent 
13a Test for Iron 
To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
solution is added. 
Absence of Blood 
red colour 
Absent 
b. To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
solution and 2 ml of 
concentrated Nitric Acid is 
added. 
Absence of Blood 
red colour. 
Absent 
14. Test for Zinc 
To the 2 ml of extract Sodium 
Hydroxide solution is added in 
drops to excess. 
 White precipitate 
Obtained . 
Present 
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 15. Test for Calcium 
2 ml of the extract is added 
with 2 ml of 4% Ammonium 
Oxalate solution. 
White precipitate 
Obtained 
Present 
16. Test for Magnesium 
 2ml of extract, Sodium 
Hydroxide solution is added in 
drops to excess. 
White precipitate 
Obtained 
Present 
17. Test for Ammonium 
 2 ml of extract few ml of 
Nessler’s Reagent and excess 
of Sodium Hydroxide solution 
are added. 
 
Absence of   
Reddish brown 
precipitate . 
 
Absent 
18. Test for Potassium 
A pinch of substance is treated 
with 2 ml of Sodium Nitrite 
solution and then treated with 2 
ml of Cobal Nitrate in 30% 
glacial Acetic acid. 
 
Absence of   Yellow 
precipitate. 
Absent 
19. Test for Sodium 
2 pinches of the substance is 
made into paste by using 
Hydrochloric acid and 
introduced into the blue flame. 
Absence of Yellow 
colour flame 
Absent 
20. Test for Mercury 
2 ml of the extract is treated 
with 2 ml of Sodium 
Hydroxide solution. 
Absence of yellow 
precipitate 
Absent 
21. Test for Arsenic 
2 ml of extract is treated with 2 
ml of silver Nitrate solution 
Absence of                                                                                                                    
Yellow precipitate. 
Absent 
22. Test for Starch 
2ml of extract is treated with 
weak iodine solution 
 
Absence of 
Bluecolour. 
Absent 
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23. Test of reducing Sugar 
5ml of Benedicts qualitative 
solution is taken in a test tube 
and allowed to boil for 2 
minutes and added  10 drops of 
the extract and again boiled for 
2 minutes.  The colour changes 
are noted. 
Absence of Green 
colour. 
Absent 
24.  Test of  the alkaliods               
2ml of the extract is treated 
with  2ml of potassium lodide 
solution. 
Absence of Red 
colour 
Absent 
25. 
 
 
 
 
Test of  the proteins 
2ml of the extract is treated 
with  2ml of 5% NaOH ,mix 
well and add 2 drops of copper 
sulphate solution. 
Absence of Violet  
colour. 
Absent 
 
 
 
 
RESULTS:   
The given sample contains. 
Drug  Name   : Velvanga Parpam 
a. Chloride 
b. Zinc 
c. Calcium 
d. Magnesium. 
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Toxicological 
study 
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ANNEXURE-II 
ACUTE AND SUB ACUTE TOXICITY STUDY ON VELVANGA PARPAM 
Animals  
 Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained 
from the animal house of Vels University. The animals were used with the approval of 
the Institute animal ethics committee and obtained from Vels University, Chennai. They 
were fed with a balanced standard pellet diet and maintained under standard laboratory 
conditions, providing 24-280C temperature, standard light cycle (12 h light, 12 h dark) 
and water ad libitum. Animals were kept in cages with raised floors of wide mesh to 
prevent coprophagy. Animal welfare guidelines were observed during the maintenance 
period and experimentation. The rats were randomly assigned to control and different 
treatment groups, six animals per group. The animals were acclimatized for one week 
under laboratory conditions.  
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Velvanga Parpam was carried out as per OECD 
Guidelines 425. As with other sequential test designs, care was taken to ensure that 
animals are available in the appropriate size and age range for the entire study. The test 
substance is administered in a single dose by gavage using a stomach tube or a suitable 
intubation cannula. The fasted body weight of each animal is determined and the dose is 
calculated according to the body weight. After the substance has been administered, food 
was withheld for a further 2 hours in mice.  
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 The animals were observed continuously for the first 4 h and then each hour for 
the next 24 h and at 6 hourly intervals for the following 48 h after administering of the 
test drug, to observe any death or changes in general behaviour and other physiological 
activities. Single animals are dosed in sequence usually at 48 h intervals. However, the 
time interval between dosing is determined by the onset, duration, and severity of toxic 
signs. Treatment of an animal at the next dose was delayed until one is confident of 
survival of the previously dosed animal. General behavior, respiratory pattern, 
cardiovascular signs, motor activities, reflexes, change in skin and fur, mortality and the 
body weight changes were monitored daily. The time of onset, intensity, and duration of 
these signs, if any, was recorded.  
SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four either sex (3+3) rats were 
divided into four groups of 6 rats each. Group I that served as normal control was 
administered with distilled water (p.o.) while groups II, III and IV were administered 
daily with the Velvanga Parpam (p.o.) for 28 days at a dose of 2.5, 5.0 and 10mg/kg 
respectively. The animals were then observed daily for gross behavioural changes and 
any other signs of subacute toxicity. The weight of each rat was recorded on day 0 and 
weekly throughout the course of the study, food and water consumption per rat was 
calculated. At the end of the 28 days they were fasted overnight, each animal was 
anaesthetized with diethylether, following which they were then dissected and blood 
samples were obtained by cardiac puncture into heparinised tubes. The blood sample 
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collected from each rat was centrifuged with 3000 X g at 4oC for 10 min to separate the 
serum and used for the biochemical assays.  
Hematological and blood biochemical analyses:  
 At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological and 
blood chemical analyses were taken from retro orbital vein. Heparinized blood samples 
were taken for determining complete blood count (white blood cell count, differential 
white blood cell count, platelet count, red blood cell count, hematocrit, and hemoglobin) 
by semiautomated hematology analyzer. The serum from non-heparinized blood was 
carefully collected for blood chemistry and enzyme analysis (glucose, creatinine, total 
protein, albumin, total and direct bilirubins, serum glutamate-oxaloacetate transaminase 
(SGOT), serum glutamate pyruvate transaminase (SGPT), and alkaline phosphatase 
(ALP)) were automatically determined using autoanalyzer. 
Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancrea, Lung, Liver, 
Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all 
rats to visually detect gross lesions, and weighed to determine relative organs’ weights 
and preserved in 10% neutral formalin for histopathological assessment. The tissues were 
embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically. 
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Statistical analysis 
 Values were represented as mean ± SEM. Data were analysed using one-way 
analysis of variance (ANOVA) using GraphPad Instat-V3 software. P values < 0.05 were 
considered significant. 
RESULTS 
 All the animals from control and all the treated dose groups up to 5mg/kg survived 
throughout the dosing period of 28 days. No signs of major or significant intoxication 
were observed in animals from lower to higher dose groups during the dosing period of 
28 days. Animals from all the treated dose groups exhibited comparable body weight gain 
with that of controls throughout the dosing period of 28 days.  
 Food consumption of control and treated animals was found to be comparable 
throughout the dosing period of 28days. Ophthalmoscopic examination, conducted prior 
to and at the end of dosing period on animals from control and all the treated dose groups 
did not reveal any abnormality. The results of haematological investigations revealed 
following significant changes in the values of different parameters investigated when 
compared with those of respective controls; However, the increase or decrease in the 
values obtained was within normal biological and laboratory limits.  
 A slight decrease in total RBC count values were obtained for animals in the dose 
group of 2.5 and 5mg/kg (P<0.05). Decreased values of platelets (P<0.05) were observed 
for animals in dose groups administered 5-10mg/ kg body weight of Velvanga Parpam 
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sacrificed on day 28. Results of Biochemical investigations conducted on days 28 and 
revealed the following significant changes in the values of different parameters studied 
when compared with those of respective controls; however, the values obtained were 
within normal biological and laboratory limits.  
 Protein level is elevated in animals of 2.5 and 5mg/kg dose group (P<0.05). 
Aspartate Amino transferase levels slightly decreased in animals of 5 and 10mg/kg group 
(P<0.01). 8) Functional observation tests conducted at termination revealed no 
abnormalities. Urine analysis, conducted at the end of the dosing period in week 4 
revealed no abnormality attributable to the treatment. Organ weight data of animals 
sacrificed at the end of the dosing period was found to be comparable with that of 
respective controls. Gross pathological examination did not reveal any abnormality. 
Histopathological examination did not reveal any abnormality. 
CONCLUSION: 
 Based on these findings, no toxic effect was observed upto 5mg/kg of Velvanga 
Parpam on oral route over a period of 28 days. So, it can be concluded that the Velvanga 
Parpam can be prescribed for therapeutic use in human with the dosage recommendations 
of upto 5mg/kg. body weight p.o. 
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Table 1: Dose finding experiment and its behavioral Signs of Toxicity 
No Dose mg/kg 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. 50 + - - + - + + - - - - - - - - - - - + - 
2 300 + + - + - + + + + - - - - - - + - + + + 
3 2000 + + - + - + + + + + - - + - - + - + + + 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased Motor Activity 8. Tremors 9. 
Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 
18. Writhing 19. Respiration 20. Mortality 
 
 
 
 
Table 2. Body wt (g) of albino rats exposed to Velvanga Parpam for 28days. 
Dose 
(mg/kg/day) 
Days 
1 7 14 21 28 
Control 210.11±5.00 212.15±4.05 214.25±5.20 218.22±6.12 221.00±5.00* 
2.5 215.00±4.31 217.12±4.52 220.31±4.16* 222.64±8.21** 224.62±6.10* 
5.0 214.13±5.00 214.10±4.82 211.00±3.18 210.10±5.00 207.72±4.21* 
10 212.32±5.20 210.20±5.40 210.12±5.24 205.02±4.38 204.12±3.12* 
Values are mean of 6 animals ± S.E.M. *P<0.05; **P<0.01.  
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Table 3. Food (g/day) intake of albino rats exposed to Velvanga Parpam for 28days. 
Dose 
(mg/kg/day) 
Days (gms/rats) 
1 7 14 21 28 
Control 45.00±2.75 44.54±2.18 46.45±2.19 45.00±2.58 47.50±3.42 
2.5 44.21±2.48 45.43±2.42 46.24±2.46 49.12±2.49 48.18±3.00 
5.0 42.35±2.10 42.00±2.54 44.20±2.42 45.81±3.56 46.40±3.00 
10 43.43±2.61 45.24±2.80 44.11±2.80 45.19±2.02 45.06±3.11 
Values are mean of 6 animals ± S.E.M. nsP>0.05Vs control. 
 
 
 
Table 4. Water (ml/day) intake of male and female albino rats exposed to Velvanga 
Parpam for 28days. 
 
Dose 
(mg/kg/day) 
Days(ml/rat) 
1 7 14 21 28 
Control 52.04±2.80 52.02±3.43 55.21±3.15 50.13±3.14 50.24±3.20 
2.5 52.28±2.42 51.20±3.04 48.20±4.02 46.18±3.00 42.52±2.48* 
5.0 48.14±2.18 50.14±3.72 44.28±3.34 42.12±2.92 44.14±3.37 
10 50.43±3.52 52.72±3.00 50.22±3.80 46.42±3.12 44.32±3.15 
Values are mean of 6 animals ± S.E.M. *P<0.05; Vs control. 
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Table 5. Hematological parameters after 28days treatment with Velvanga Parpam in 
rats. 
Parameter Control 2.5 mg/kg 5 mg/kg 10 mg/kg 
Red blood cell 
(mm3) 
8.18±0.72 7.59±0.44 7.25±0.52 7.13±0.50 
HB (%) 14.42±0.30 12.10±0.35 12.51±0.40 11.02±0.44* 
Leukocyte 
(x106/mL) 
10215±112.55 10415±215.14 10206±224.11 10346±212.00 
Platelets/ul 1440±34.10 1392±32.12 1172±30.22** 998±23.16** 
MCV (gl) 55.62±5.42 55.10±5.72 55.45±5.22 56.18±4.62 
Neutrophil 5.54±1.43 5.22±1.20 4.84±0.92* 5.14±3.27 
Lymphocyte 92.32±2.90 91.48±3.12 93.20±3.24 94.30±3.86 
Monocyte 2.15±0.30 2.31±0.34 2.25±0.22 2.28±0.31 
Eosinophil 1.00±0.00  1.0±0.22  1.0±0.11 1.00±0.12 
Basophil 0 0 0 0 
ESR(mm) 1±00 1±00 1±00 1±00 
PCV 42.30±2.52 45.11±2.18 45.52±3.04 45.42±3.00 
Values are mean of 6 animals ± S.E.M. *P<0.05; **P<0.01. Vs control. 
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Table 6. Effect of treatment with Velvanga Parpam biochemical 
parameters. 
 
Dose (mg/kg) Control 2.5 mg/kg 5 mg/kg 10 mg/kg 
Total Bilirubin (mg/dL) 0.200±0.05 0.220±0.06** 0.225±0.05** 0.218±0.04** 
Bilirubin direct 
(mg/dL) 
0.1±0.04 0.1±0.05 0.1±0.04 0.1±0.05 
Bilirubin 
indirect(mg/dL) 
0.1±00 0.1±00 0.1±00 0.1±00 
ALP (U/L) 380.32±10.10 414.20±12.13** 456.82±10.02 494.21±12.22 
SGOT (U/L) 176.21±5.18 160.26±6.52** 156.23±5.10* 154.12±5.50* 
SGPT(U/L) 45.2±2.32 44.18±3.22 45.83±2.52 44.60±4.17 
Total Protein(g/dl) 9.02±1.22 8.07±0.30* 8.15±0.27* 8.10±0.42* 
Albumin(g/dl) 3.17±0.25 3.10±0.24 3.16±0.23 3.10±0.22 
Globulin(g/dl) 5.00±0.18 4.18±0.22* 4.28±0.24* 4.28±0.23* 
Values are mean of 6 animals ± S.E.M. *P<0.05; **P<0.01. Vs control.  
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Table-7 RFT 
 
 
Dose (mg/kg) Control 2.5 mg/kg 5 mg/kg 10 mg/kg 
Urea(mg/dL) 55.40±2.35 54.32±3.62 55.42±2.18 55.82±2.30 
Creatinine (mg/dL) 0.77±0.05 0.76±0.05 0.78±0.06 0.76±0.05 
Uric acid (mg/dL) 1.62±0.12 1.16±0.18** 1.26±0.16* 1.06±0.12** 
Na m.mol 142.80±5.22 144.5±5.00 142.12±5.22 140.28±5.10 
K m.mol 20.45±2.48 19.40±2.60 20.05±2.42 20.18±2.02 
Cl m.mol 100.25±4.46 100.20±5.22 99.78±4.72 100.02±4.10 
 
Values are mean of 6 animals ± S.E.M. *P<0.05; **P<0.01. Vs control.  
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Table-8. Lipid Profile 
 
 
Dose (mg/kg) Control 2.5 mg/kg 5 mg/kg 10 mg/kg 
Total cholestrol(mg/dL) 40.82±2.52 41.10±2.42 40.28±3.24 41.00±3.01 
HDL(mg/dL) 13.02±1.42 13.20±1.47 13.20±2.42 13.24±2.23 
LDL(mg/dL) 44.00±2.80 44.05±3.60 43.38±3.20 44.22±3.20 
VLDL(mg/dl) 16.32±2.60 15.22±2.42 16.10±1.42 15.00±1.14 
Triglycerides (mg/dl) 86.04±3.02 85.18±2.22 86.32±3.40 85.14±2.72 
TC/HDL ratio (g/dl) 3.66±0.25 3.70±0.28 3.70±0.30 3.52±0.28 
Blood glucose(mg/dl) 125.30±6.47 126.05±5.20 126.15±5.62 125.21±2.57 
 
Values are mean of 6 animals ± S.E.M. nsP>0.05; Vs control. 
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Table-9 Urine Analysis 
 
 
Parameters Control 2.5 mg/kg 5 mg/kg 10 mg/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly turbid Slightly 
cloudy 
Slightly turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >8.0 >9.0 
Protein Nil 3+ 3+ 3+ 
Glucose Nil Nil Nil Nil 
Bilirubin -ve -ve -ve -ve 
Ketones -ve +ve +ve +ve 
Blood Absent Absent Absent Absent 
Urobilinogen Normal Abnormal Abnormal Abnormal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria seen Bacteria seen 
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Table 10. Effect of oral administration of a Velvanga Parpam on organ weight 
 
 
 
Dose (mg/kg) Control 2.5 mg/kg 5 mg/kg 10 mg/kg 
Liver (g) 5.27±0.17 5.00±0.15 4.82±0.12 4.71±0.18* 
Heart (g) 0.62±0.04 0.60±0.05 0.58±0.04 0.58±0.04 
Lung (g) 1.45±0.06 1.44±0.14 1.46±0.24 1.50±0.15** 
Spleen (g) 0.65±0.05 0.65±0.04 0.66±0.04 0.65±0.05 
Ovary (g) 1.71±0.14 1.73±0.15 1.70±0.18 1.72±0.15 
Testes (g) 1.48±0.10 1.45±0.12 1.46±0.15 1.46±0.15 
Brain (g) 1.56±0.15 1.58±0.13 1.56±0.14 1.53±0.14 
Kidney (g) 0.73±0.04 0.71±0.04 0.70±0.04 0.72±0.05 
Stomach (g) 1.36±0.14 1.35±0.12 1.36±0.11 1.35±0.15 
 
Values are mean of 6 animals ± S.E.M. *P<0.05; **P<0.01 Vs control. 
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DRUG OF VELVANGA PARPAM 
HISTOPATHOLOGY 
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ANNEXURE- III 
ANTITUMOR ACTIVITY OF VELVANGA PARPAM IN RODENTS 
INTRODUCTION: 
 In most people's minds there is no scarier diagnosis than that of cancer.  Cancer is 
often thought of as an untreatable, unbearably painful disease with no cure. However 
popular this view of cancer may be, it is exaggerated and over-generalized. Cancer is 
undoubtedly a serious and potentially life-threatening illness. The truth of the matter is 
that there are multiple types of cancer, many of which can today be effectively treated so 
as to eliminate, reduce or slow the impact of the disease on patients' lives. While a 
diagnosis of cancer may still leave patients feeling helpless and out of control, in many 
cases today there is cause for hope rather than hopelessness. Normal cells in the body 
grow and divide for a period of time and then stop growing and dividing. Thereafter, they 
only reproduce themselves as necessary to replace defective or dying cells. Cancer occurs 
when this cellular reproduction process goes out of control. In other words, cancer is a 
disease characterized by uncontrolled, uncoordinated and undesirable cell division. 
Unlike normal cells, cancer cells continue to grow and divide for their whole lives, 
replicating into more and more harmful cells. The abnormal growth and division 
observed in cancer cells is caused by damage in these cells' DNA (genetic material inside 
cells that determines cellular characteristics and functioning). There are a variety of ways 
that cellular DNA can become damaged and defective. Alternatively, defective DNA can 
be inherited from your parents. As cancer cells divide and replicate themselves, they 
often form into a clump of cancer cells known as a tumor. Tumors cause many of the 
symptoms of cancer by pressuring, crushing and destroying surrounding non-cancerous 
cells and tissues. Tumors come in two forms; benign and malignant. Benign tumors are 
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not cancerous, thus they do not grow and spread to the extent of cancerous tumors. 
Benign tumors are usually not life threatening. Malignant tumors, on the other hand, 
grow and spread to other areas of the body. The process whereby cancer cells travel from 
the initial tumor site to other parts of the body is known as metastasis. The causes of 
cancer are not fully understood, but years of research have brought to light risk factors 
that increase people's chances of getting particular types of cancer. Some of these risk 
factors are inevitable, while others can be avoided by choosing to live a healthy lifestyle.  
The Normal Prostate Gland 
 The prostate is a walnut-sized gland that forms part of the male reproductive 
system. The gland is made of two lobes, or regions, enclosed by an outer layer of tissue. 
As the diagrams show, the prostate is located in front of the rectum and just below the 
bladder, where urine is stored. The prostate also surrounds the urethra, the canal through 
which urine passes out of the body. Scientists do not know all the prostate's functions. 
One of its main roles, though, is to squeeze fluid into the urethra as sperm move through 
during sexual climax. This fluid, which helps make up semen, energizes the sperm and 
makes the vaginal canal less acidic.  
 The normal prostate is composed of glands and stroma. The glands are seen in 
cross section to be rounded to irregularly branching. These glands represent the terminal 
tubular portions of long tubuloalveolar glands that radiate from the urethra. The glands 
are lined by two cell layers: an outer low cuboidal layer and an inner layer of tall 
columnar mucin-secreting epithelium. These cells project inward as papillary projections. 
The fibromuscular stroma between the glands accounts for about half of the volume of 
the prostate.  
Prostatitis 
 Acute prostatitis is not common, but is most likely to occur in young men. 
Causative agents include bacterial organisms similar to those causing urinary tract 
infections, as well as Neisseria gonorrheae. A related complication of prostatic abscess is 
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uncommon. The and slight enlargement of the prostate with acute inflammation may 
cause acute rectal, lower back, or perineal pain along with fever. There can be dysuria. 
The prostate is enlarged and tender. Urine culture may be done, but prostatic massage is 
contraindicated. Microscopically, the glands are filled with neutrophils, and the 
intervening stroma may also contain a few neutrophils, explaining the presence of 
neutrophils on urine microscopic examination. 
  
Chronic prostatitis may follow acute prostatitis, but is more likely to occur without 
prior history in older men, and may suggest an underlying obstructive urinary tract 
abnormality. There can be intermittent urinary frequency and dysuria. The prostate may 
not be enlarged. Prostatic massage may increase the yield of urine culture. Routine 
cultures, however, do not identify one common organism: Ureaplasma urealyticum.  
 Chronic abacterial prostatitis is the most common cause for prostatitis, but is 
difficult to diagnose from lack of specific findings. No organism can be identified as a 
causative agent. Symptoms of dysuria along with low grade pelvic pain or low back pain 
may be present. Microscopically, lymphocytes, plasma cells, and macrophages appear in 
the prostatic stroma. Prostatitis can elevate the serum prostate specific antigen, but 
generally not more than double normal, and generally not increasing significantly over 
time. 
 
Prostatic Hyperplasia 
 Nodular prostatic hyperplasia (benign prostatic hyperplasia, or BPH) is a common 
condition as men age. The mechanism for hyperplasia may be related to accumulation of 
dihydrotestosterone in the prostate, which then binds to nuclear hormone receptors which 
then trigger growth. The normal prostate weighs 20 to 30 gm, but most prostates with 
nodular hyperplasia can weigh from 50 to 100 gm.  
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Diagram illustrating normal prostate (left) and benign prostatic hyperplasia (right). 
                                        
Prevalence and Incidence of BPH 
 Benign prostatic hyperplasia (BPH) is the proliferation of nonmalignant stromal 
and epithelial cells in the prostate, which may lead to nodular formation in the 
periurethral area of the prostate and subsequent partial or complete obstruction of the 
urethra. Clinical BPH is a diagnosis of lower urinary tract symptoms (LUTS), urinary 
tract infections (UTIs), or acute urinary retention due to the urethral obstruction. BPH 
progresses linearly with age. According to the National Institutes of Health, there are 
more than 7.8 million BPH diagnoses made.  Histological evidence of BPH emerges 
after age 30, with 50% prevalence in men age 50-61 and 90% prevalence by age 
90. However, it is difficult to predict how many of these cases will progress to clinical 
BPH. The overall prevalence of clinical BPH (BPH with LUTS) is 10.3%, with a 
maximum prevalence of 24% by age 80. It is estimated that 45% of nonsymptomatic 46-
year-old men with histological BPH will develop LUTS over the next 30 years.  
 The cause of BPH is not well understood. No definite information on risk factors 
exists. Theory focuses on dihydrotestosterone (DHT), a substance derived from 
testosterone prostate, which may help control its growth. Most animals lose their ability 
to produce DHT as they age. However, some research has indicated that even with a drop 
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in the blood's testosterone level, older men continue to produce and accumulate high 
levels of DHT in the prostate. This accumulation of DHT may encourage the growth of 
cells. Scientists have also noted that men who do not produce DHT do not develop BPH. 
Signs and Symptoms of BPH 
Symptoms 
Screening and diagnostic procedures for BPH are similar to those used for prostate 
cancer. Some signs to look for include:  
• Weak urinary stream 
• Prolonged emptying of the bladder 
• Abdominal straining 
• Hesitancy 
• Irregular need to urinate 
• Incomplete bladder emptying 
• Post-urination dribble 
• Irritation during urination 
• Frequent urination 
• Nocturia (need to urinate during the night) 
• Urgency 
• Incontinence (involuntary leakage of urine) 
•      Bladder pain  
•      Dysuria (painful urination) 
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•      Problems in ejaculation 
 
 The size of the prostate does not always determine how severe the obstruction or 
the symptoms will be. Some men with greatly enlarged glands have little obstruction and 
few symptoms while others, whose glands are less enlarged, have more blockage and 
greater problems. In most males, the prostate gland slowly begins to enlarge around the 
age of 30, but it is usually asymptomatic until age 50. An enlarged prostate can cause 
both obstructive (voiding) and irritative (holding) symptoms that decrease a patient’s 
quality of life. BPH may lead to UTIs and AUR, which may require surgical intervention, 
but these are often preceded by LUTS.  Obstructive symptoms include decreased force 
of the urinary stream, straining to urinate and hesitancy to initiate urination, interruptions 
in flow, and the feeling of not emptying the bladder. Irritative symptoms include 
frequency, nocturia, dysuria, urgency, and urge incontinence. These symptoms may 
decrease a patient’s quality of life by interfering with his ability to perform his job, to 
travel, to attend social engagements, and to get a good night’s sleep. Depending on the 
individual, only some of these symptoms may be present, and to varying degrees of 
severity. 
 A digital rectal exam may reveal an enlarged prostate. An elevated PSA level may 
also signify an enlarged prostate, among other possible diagnoses, and should be 
followed by a free PSA determination. 
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   Normal urine flow                   Urine flow with BPH. 
As a man matures, the prostate goes through two main periods of growth. The first 
occurs early in puberty, when the prostate doubles in size. At around age 25, the gland 
begins to grow again. This second growth phase often results, years later, in BPH. 
Though the prostate continues to grow during most of a man's life, the enlargement 
doesn't usually cause problems until late in life. BPH rarely causes symptoms before age 
40, but more than half of men in their sixties and as many as 90 percent in their seventies 
and eighties have some symptoms of BPH. 
 As the prostate enlarges, the layer of tissue surrounding it stops it from expanding, 
causing the gland to press against the urethra like a clamp on a garden hose. The bladder 
wall becomes thicker and irritable. The bladder begins to contract even when it contains 
small amounts of urine, causing more frequent urination. Eventually, the bladder weakens 
and loses the ability to empty itself, so some of the urine remains in the bladder. The 
narrowing of the urethra and partial emptying of the bladder cause many of the problems 
associated with BPH. 
Sometimes a man may not know he has any obstruction until he suddenly finds himself 
unable to urinate at all. This condition, called acute urinary retention, may be triggered by 
taking over-the-counter cold or allergy medicines.  
Such medicines contain a decongestant drug, known as a sympathomimetic. A potential 
side effect of this drug may prevent the bladder opening from relaxing and allowing urine 
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to empty. When partial obstruction is present, urinary retention also can be brought on by 
alcohol, cold temperatures, or a long period of immobility. 
It is important to tell your doctor about urinary problems such as those described above. 
In eight out of 10 cases, these symptoms suggest BPH, but they also can signal other, 
more serious conditions that require prompt treatment. These conditions, including 
prostate cancer, can be ruled out only by a doctor's examination. 
 Severe BPH can cause serious problems over time. Urine retention and strain on 
the bladder can lead to urinary tract infections, bladder or kidney damage, bladder stones, 
and incontinence-the inability to control urination. If the bladder is permanently 
damaged, treatment for BPH may be ineffective. When BPH is found in its earlier stages, 
there is a lower risk of developing such complications. 
Diagnosis 
Prostate with a large median lobe bulging upwards. 
 
When BPH is suspected, it may be referred to urologist, a doctor who specializes in 
problems of the urinary tract and the male reproductive system. Several tests help the 
doctor identify the problem and decide whether surgery is needed. The tests vary from 
patient to patient, but the following are the most common. 
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Digital Rectal Examination  
 This examination is usually the first test done. The doctor inserts a gloved finger 
into the rectum and feels the part of the prostate next to the rectum. This examination 
gives the doctor a general idea of the size and condition of the gland. 
Prostate-Specific Antigen (PSA) Blood Test 
 To rule out cancer as a cause of urinary symptoms, doctor may recommend a PSA 
blood test. PSA, a protein produced by prostate cells, is frequently present at elevated 
levels in the blood of men who have prostate cancer. Prostate cancers may be detected by 
digital examination, by ultrasonography (transrectal ultrasound), or by screening with a 
blood test for prostate specific antigen (PSA). None of these methods can reliably detect 
all prostate cancers, particularly the small cancers. Widespread PSA screening is not cost-
effective. PSA is a glycoprotein produced almost exclusively in the epithelium of the 
prostate gland. In the circulation PSA may be complexed to serum proteins (complexed 
PSA, or cPSA) or may be free (fPSA). The cPSA and fPSA together comprise total PSA 
(tPSA).  
 The tPSA is normally less than 4 ng/mL. A mildly increased tPSA in a patient 
with a very large prostate can be due to nodular hyperplasia, or to prostatitis. The fPSA 
correlates more closely with benign prostatic conditions than the tPSA. Men who have 
findings suspicious for carcinoma on digital rectal examination and a tPSA of <4 ng/mL 
have a probability of cancer of at least 10%, while those with tPSA levels from 4 to 10 
ng/mL have a 25% probability. Men with tPSA's above 10 ng/mL have a >50% 
likelihood of having a prostate cancer.  
Rectal Ultrasound and Prostate Biopsy 
 If there is a suspicion of prostate cancer, your doctor may recommend a test with 
rectal ultrasound. In this procedure, a probe inserted in the rectum directs sound waves at 
the prostate. The echo patterns of the sound waves form an image of the prostate gland on 
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a display screen. To determine whether an abnormal-looking area is indeed a tumor, the 
doctor can use the probe and the ultrasound images to guide a biopsy needle to the 
suspected tumor. The needle collects a few pieces of prostate tissue for examination with 
a microscope. 
Urine Flow Study 
 Doctor may ask patient to urinate into a special device that measures how quickly 
the urine is flowing. A reduced flow often suggests BPH. 
 
Cystoscopy 
 In this examination, the doctor inserts a small tube through the opening of the 
urethra in the penis. This procedure is done after a solution numbs the inside of the penis 
so all sensation is lost. The tube, called a cystoscope, contains a lens and a light system 
that help the doctor see the inside of the urethra and the bladder. This test allows the 
doctor to determine the size of the gland and identify the location and degree of the 
obstruction. 
Treatment 
 Men who have BPH with symptoms usually need some kind of treatment at some 
time. However, a number of researchers have questioned the need for early treatment 
when the gland is just mildly enlarged. The results of their studies indicate that early 
treatment may not be needed because the symptoms of BPH clear up without treatment in 
as many as one-third of all mild cases.  
 Instead of immediate treatment, they suggest regular checkups to watch for early 
problems. If the condition begins to pose a danger to the patient's health or causes a major 
inconvenience to him, treatment is usually recommended. 
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Since BPH can cause urinary tract infections, a doctor will usually clear up any infection 
with antibiotics before treating the BPH itself. Although the need for treatment is not 
usually urgent, doctors generally advise going ahead with treatment once the problems 
become bothersome or present a health risk. 
Drug Treatment 
 Finasteride, and dutasteride, inhibit production of the hormone DHT, which is 
involved with prostate enlargement. The use of either of these drugs can either prevent 
progression of growth of the prostate or actually shrink the prostate in some men. 
Also Terazosin, doxazosin, tamsulosin, and alfuzosin are currently used for the 
treatment of BPH. All four drugs act by relaxing the smooth muscle of the prostate and 
bladder neck to improve urine flow and to reduce bladder outlet obstruction. The four 
drugs belong to the class known as alpha blockers. Terazosin and doxazosin were 
developed first to treat high blood pressure. Tamsulosin and alfuzosin were developed 
specifically to treat BPH. 
Transurethral microwave procedures  
 In the procedure called transurethral microwave thermotherapy (TUMT), the 
device sends computer-regulated microwaves through a catheter to heat selected portions 
of the prostate to at least 111 degrees Fahrenheit. A cooling system protects the urinary 
tract during the procedure. The procedure takes about 1 hour and can be performed on an 
outpatient basis without general anesthesia. TUMT has not been reported to lead to 
erectile dysfunction or incontinence. 
Transurethral needle ablation  
 The TUNA system delivers low-level radiofrequency energy through twin needles 
to burn away a well-defined region of the enlarged prostate. Shields protect the urethra 
from heat damage. The TUNA system improves urine flow and relieves symptoms with 
146 
   
fewer side effects when compared with transurethral resection of the prostate (TURP). 
No incontinence or impotence has been observed. 
Water-induced thermotherapy 
 This therapy uses heated water to destroy excess tissue in the prostate. A catheter 
containing multiple shafts is positioned in the urethra so that a treatment balloon rests in 
the middle of the prostate. A computer controls the temperature of the water, which flows 
into the balloon and heats the surrounding prostate tissue. The system focuses the heat in 
a precise region of the prostate. Surrounding tissues in the urethra and bladder are 
protected. Destroyed tissue either escapes with urine through the urethra or is reabsorbed 
by the body. 
High-intensity focused ultrasound 
 The use of ultrasound waves to destroy prostate tissue is still undergoing clinical 
trials in the United States. The FDA has not yet approved high-intensity focused 
ultrasound. 
Surgical Treatment 
 Most doctors recommend removal of the enlarged part of the prostate as the best 
long-term solution for patients with BPH. With surgery for BPH, only the enlarged tissue 
that is pressing against the urethra is removed; the rest of the inside tissue and the outside 
capsule are left intact. Surgery usually relieves the obstruction and incomplete emptying 
caused by BPH. The following section describes the types of surgery that are used. 
 
Transurethral surgery 
 In this type of surgery, no external incision is needed. After giving anesthesia, the 
surgeon reaches the prostate by inserting an instrument through the urethra. 
A procedure called transurethral resection of the prostate (TURP) is used for 90 percent 
of all prostate surgeries done for BPH. With TURP, an instrument called a resectoscope 
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is inserted through the penis. The resectoscope, which is about 12 inches long and 1/2 
inch in diameter, contains a light, valves for controlling irrigating fluid, and an electrical 
loop that cuts tissue and seals blood vessels. 
 
Open surgery  
 In the few cases when a transurethral procedure cannot be used, open surgery, 
which requires an external incision, may be used. The location of the enlargement within 
the gland and the patient's general health help the surgeon decide which of the three open 
procedures to use. With the open procedures, anesthesia is given and an incision is made. 
Once the surgeon reaches the prostate capsule, he or she scoops out the enlarged tissue 
from inside the gland. 
 
Laser surgery   
 The doctor passes the laser fiber through the urethra into the prostate using a 
cystoscope and then delivers several bursts of energy lasting 30 to 60 seconds. The laser 
energy destroys prostate tissue and causes shrinkage. As with TURP, laser surgery 
requires anesthesia and a hospital stay. One advantage of laser surgery over TURP is that 
laser surgery causes little blood loss. Laser surgery also allows for a quicker recovery 
time. But laser surgery may not be effective on larger prostates.  
 
Photoselective vaporization of the prostate  
 PVP uses a high-energy laser to destroy prostate tissue and seal the treated area. 
Interstitial laser coagulation.  
 Unlike other laser procedures, interstitial laser coagulation places the tip of the 
fiberoptic probe directly into the prostate tissue to destroy it. 
Sexual Function After Surgery 
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 Complete recovery of sexual function may take up to 1 year, lagging behind a 
person's general recovery. The exact length of time depends on how long after symptoms 
appeared that BPH surgery was done and on the type of surgery.  
Need for the study and selection of methodology 
 Hyperplasia begins in the region of the veru-montanum, in the inner zone of the 
prostate, and extends to involve lateral lobes. This enlargement impinges upon the 
prostatic urethra, leading to the difficulty on urination with hesitency that is typical for 
this condition. Dysuria, dribbling, and nocturia are also frequent. The urinary tract 
obstruction leads to urinary retention and risk for infection. In severe, prolonged cases, 
hydroureter with hydronephrosis and renal failure can ensue. The main reason is cell 
multiplication during enlargement. With this logic this investigation was correlated in the 
DAL lymphoma cancer cell lines proliferation in animal models to ascertain the efficacy 
of the Velvanga parpam in the reduction of cell multiplication rate with respect to the 
prostatic hyperplasia.  
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MATERIALS AND METHODS 
Animals Used 
 Swiss albino mice (20-25g) were used throughout the study. They were housed in 
standard microlon boxes and were given standard laboratory diet and water ad libitum. 
Tumour cell lines 
Dalton Ascitis Lymphoma (DAL) cells were obtained through the courtesy of Amala 
Cancer Research Centre, Thrissur, Kerala. DAL cells were maintained by weekly 
interaperitoneal (i.p) inoculation of 1 x 106 cells/mouse. 
Effect of Velvanga Parpam on survival time 
 Animals were inoculated with 1x106 cells/mouse on day ‘0’ and treatment with 
Velvanga Parpam started 24h after inoculation, at the doses of 1.5 and 3mg/kg/day orally. 
The control group was treated with same volume of 0.9% sodium chloride solution. All 
treatments were carried out for 9 days and observation was carried out for 45 days. The 
animals were subjected for the analysis of median survival time (MST) of each group 
(n=6) and changes in body weight. The antitumour efficacy of Velvanga Parpam was 
compared with that of 5 Fluorouracil (20mg/kg/day i.p. for 9 days). MST was noted with 
reference to control. Survival times of the treated group (T) were compared with those of 
the control groups (C) using the following calculation. 
    T--C 
Increase of life span =     __________x 100 
       C 
Where T = number of days treated animals survived and C = number of days control 
animal survived. 
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Effect of Velvanga Parpam on haemotological parameters 
 In order to detect the influence of Velvanga Parpam on the haemotological status 
of DAL bearing mice, comparison was made amongst three groups (n=6) of mice on the 
14th day after inoculation. The three groups comprised (1) tumour bearing mice, (2) 
tumour bearing mice treated with Velvanga Parpam respectively (1.5 and 3mg/kg/day 
p.o. for first 9 days) and (3) control mice. Blood was drawn from each mouse in the 
conventional way and the white blood cell count, red blood cell count, haemoglobin, 
protein and packed cell volume were determined. The ascetic fluids were collected on 
14th day and smeared. The smear was stained with Giemsa stain for cytological studies. 
Effect of Velvanga Parpam on solid tumour 
 Mice were divided into two groups (n=6). Tumour cells (1x106 cells/mice) were 
injected into the right hind limb of all the animals intramuscularly. Mice of group I were 
tumour control. Group II received Velvanga Parpam respectively (1.5 and 3mg/kg) orally 
for 5 alternate days. Tumour mass was measured from 11th day of tumour induction and 
was repeated every 5th day for a period of 30 days. The volume of tumour mass was 
calculated using the formula V-4/3 π r2 where is the mean of r1 and r2 which are two 
independent radii of the tumour mass. 
Statistical analysis 
 All the values were expressed as mean ± SEM. The data was statistically analyzed 
by one-way ANOVA followed by Dunnett’s test. P values < 0.05 were considered 
significant.  
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RESULTS AND DISCUSSION 
Antitumour studies 
Mean Survival Time (MST) 
 Any potential anticancer drug is expected to increase the mean survival time and 
thus increasing life expectancy. Mice transplanted with DAL in our studies have MST of 
22 days, which was increased to 26 and 34.32 days by Velvanga Parpam 1.5 and 3mg/kg 
respectively. These results are almost comparable to that of 5-FU, the standard drug for 
which the MST was 41.21 days. 
Haematological Parameters 
 In malignancy there is always an alteration of various haematological parameters 
which increase in a few and decrease in others. There is a decrease in Hb, RBC and 
lymphocytes in malignancy accompanied by an increase in WBC especially Neutrophils, 
protein and PCV.  
These changes are due to iron deficiency or due to haemolytic of myelopathic conditions 
induced by malignancy. Velvanga Parpam have very well reverted the above 
haematological parameters altered by the transplantable tumour of DAL. Velvanga 
Parpam may have direct tumoricidal effect and thereby maintain normal haematological 
profile. 
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Solid tumour volume 
 Estimation of solid tumour volume is a direct method of evaluation of anticancer 
activity. It is indeed a suitable method, which does not involve sacrificing the animal. In 
the study, the tumour mass was directly measured after implantation intramuscularly. The 
solid tumour volume was increased by 6.63±0.13 DAL bearing mice, treatment with 
Velvanga Parpam decreased significantly (P<0.01) the tumour volume to 4.15 ± 0.09 ml 
respectively on dose dependent manner at the end of 30 days.  
 The reliable criteria for evaluating an anticancer drug are prolongation of lifespan 
of the animal and decrease in WBC count of blood. Our results show an increase in life 
span accompanied by a reduction in WBC count in Velvanga Parpam treated mice. These 
results clearly demonstrate the antitumour effect of Velvanga Parpam against DAL. 
The common problems encountered in cancer chemotherapy are myelosuppression and 
anaemia. Anaemia occurring in tumour bearing mice is mainly due to reduction in RBC 
or hemoglobin production, and this may occur either due to iron deficiency or due to 
haemolytic or other myelopathic conditions. Treatment with Velvanga Parpam brought 
back the hemoglobin content, RBC and WBC counts to near normal. This indicates that 
Velvanga Parpam have a protective effect on the haemopoietic system.  
 Further, analysis of haemotological parameters showed minimum toxic effect in 
mice treated with Velvanga Parpam. In DAL bearing mice, haematological parameters 
were reversed to normal by Velvanga Parpam administration (9 days). 
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Cytological studies of ascetic fluid on the 14th day in DAL bearing mice revealed that the 
tumour cells are large in size showed binucleation. In Velvanga Parpam 1.5 and 3mg/kg 
treated animals bearing DAL, the cells, showed plasmacytoid feature with varying degree 
of degeneration and cytoplasmic vacuolation and also showed active mitosis. All these 
cytological studies indicate the cytotoxic effect of Velvanga Parpam. 
 In DAL bearing mice, there was a regular and rapid increase in ascitic fluid 
volume. Ascitic fluid is the direct nutritional source for tumour growth, it meets the 
nutritional requirement of tumour cells. Velvanga Parpam treatment decreased the 
volume of solid tumour as well as ascites volume, viable cancer cell count and increased 
the life span. It may be concluded that Velvanga Parpam decrease the nutritional fluid 
volume and thereby arrest the tumour growth and increase the life span. 
CONCLUSION 
 In the present study the Velvanga Parpam was studied for its antitumour effect 
against transplantable tumour. 
 The antitumor effect of the Velvanga Parpam is evident from the increase in 
lifespan, reduction in solid tumour volume and also the reversal of altered 
haematological parameter almost equal to normal. 
 All these data confirms that the Velvanga Parpam can be used as a novel potential 
agent in the area of cancer chemotherapy. 
  
154 
   
REFERENCES 
1. Anand V Naigaonkar and M.D Burande, 2004, A Manual of Medical Laboratory 
Technology, Nirali Prakasan. Pune. P 12-37. 
2. Andríole G, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the 
prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of 
benign prostatic hyperplasia. J Urol. 2004;172(4 Pt 1):1399-403. 
3. Ansari, Mohammad Abduljalil; Begum, Dilruba; Islam, Fakhrul (2008). "Serum 
sex steroids, gonadotrophins and sex hormone-binding globulin in prostatic 
hyperplasia". Annals of Saudi Medicine 28 (3): 174–8.  
4. Anti cancer activity of Ocimum sanctum,  J of Pharma Biolo ., Vol 37 ( 4) , P 285- 
290. 
5. Aua Practice Guidelines, Committee (2003). "AUA Guideline on Management of 
Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment 
Recommendations". The Journal of Urology 170 (2 Pt 1): 530–47. 
6. Auffenberg GB, Helfand BT, McVary KT. Established medical therapy for benign 
prostatic hyperplasia. Urol Clin North Am. 2009;36:443-459. 
7. Ayala AG, Ro JY. Prostatic intraepithelial neoplasia: recent advances. Arch Pathol 
Lab Med. 2007;131:1257-1266. 
8. B Rajkapoor, B Jayakar and N Murugesh ,2004, Anti tumour activity of Indigofera 
aspalathoides on Ehrlich ascites carcinoma in mice.Indi.J.Pharmacol. Vol. 36, P 
38-40. 
155 
   
9. Barry MJ, Fowler FJ, O'Leary MP, et al.(November 1992). "The American 
Urological Association symptom index for benign prostatic hyperplasia. The 
Measurement Committee of the American Urological Association". The Journal of 
Urology 148 (5): 1549–57; discussion 1564.  
10. Bent, Stephen; Kane, Christopher; Shinohara, Katsuto; Neuhaus, John; Hudes, 
Esther S.; Goldberg, Harley; Avins, Andrew L. (2006). "Saw Palmetto for Benign 
Prostatic Hyperplasia". New England Journal of Medicine 354 (6): 557–66.  
11. Black, L; Naslund, MJ; Gilbert Jr, TD; Davis, EA; Ollendorf, DA (2006). "An 
examination of treatment patterns and costs of care among patients with benign 
prostatic hyperplasia". The American journal of managed care 12 (4 Suppl): S99–
S110.  
12. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. 
Cancer. 2004;101(10 Suppl):2371-2490. 
13. Bostwick DG. Prospective origins of prostate carcinoma. Prostatic intraepithelial 
neoplasia and atypical adenomatous hyperplasia. Cancer. 1996;78:330-336. 
14. Bostwick, D. G. (2002). "The Pathology of Benign Prostatic Hyperplasia". In 
Kirby, Peter; McConnell, John D.; Fitzpatrick, John M. et al.. Textbook of Benign 
Prostatic Hyperplasia. London: Isis Medical Media. ISBN 978-1-901865-55-4. 
15. Boyle, P; Robertson, C; Lowe, F; Roehrborn, C (2000). "Meta-analysis of clinical 
trials of Permixon in the treatment of symptomatic benign prostatic 
hyperplasia". Urology 55 (4): 533–9.  
156 
   
16. Bushman W. Etiology, epidemiology, and natural history of benign prostatic 
hyperplasia. Urol Clin North Am. 2009;36:403-415. 
17. Christensen, Tyler L.; Andriole, Gerald L. (February 2009). "Benign Prostatic 
Hyperplasia: Current Treatment Strategies". Consultant 49 (2): 115–22. 
18. Dedhia, R; McVary, K (2008). "Phytotherapy for Lower Urinary Tract Symptoms 
Secondary to Benign Prostatic Hyperplasia". The Journal of Urology 179 (6): 
2119-25. 
19. Demura T, Shinohara N, Tanaka M, et al. The proportion of free to total prostate 
specific antigen: a method of detecting prostate carcinoma. Cancer. 1996;77:1137-
1143. 
20. Djavan, Bob; Marberger, Michael (1999). "A Meta-Analysis on the Efficacy and 
Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract 
Symptoms Suggestive of Benign Prostatic Obstruction". European Urology 36 (1): 
1–13. 
21. Epstein JI. An update of the Gleason grading system. J Urol. 2010;183:433-40. 
22. Feldman, Brian J.; Feldman, David (2001). "The development of androgen-
independent prostate cancer". Nature Reviews Cancer 1 (1): 34–45. 
23. Ganesh Chandra Jageti and Shival Kamalaksha Rao, 2006, evaluation of the 
antineoplastic activity of Guduchi( Tinospora cordifolia) in Ehrlich ascites 
carcinoma in bearing mice. J. Biol.Pharm.Bull. Vol. 29(3), P 460-466. 
157 
   
24. Gat, Y; Gornish, M; Heiblum, M; Joshua, S (2008). "Reversal of benign prostate 
hyperplasia by selective occlusion of impaired venous drainage in the male 
reproductive system: novel mechanism, new treatment". Andrologia40 (5): 273–
281.  
25. Gat, Yigal; Gornish, Michael (2009)."Reversal of Benign Prostate Hyperplasia by 
Super-selective Intraprostatic Androgen Deprivation Therapy". European Urology 
Review(Touch Briefings): 10–4. 
26. Gilling, Peter J.; Aho, Tevita F.; Frampton, Christopher M.; King, Colleen J.; 
Fraundorfer, Mark R. (2008). "Holmium Laser Enucleation of the Prostate: 
Results at 6 Years". European Urology 53 (4): 744–9. 
27. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol. 
1992;23:273-279. 
28. Gormley, Glenn J.; Stoner, Elizabeth; Bruskewitz, Reginald C.; Imperato-
Mcginley, Julianne; Walsh, Patrick C.; McConnell, John D.; Andriole, Gerald L.; 
Geller, Jack et al. (1992). "The Effect of Finasteride in Men with Benign Prostatic 
Hyperplasia". New England Journal of Medicine 327 (17): 1185–91. 
29. Helpap BG, Bostwick DG, Montironi R. The significance of atypical adenomatous 
hyperplasia and prostatic intraepithelial neoplasia for the development of prostate 
carcinoma. An update. Virchows Arch. 1995;426:425-434. 
30. Ho, C. K M; Nanda, J.; Chapman, K. E; Habib, F. K (2008). "Oestrogen and 
benign prostatic hyperplasia: effects on stromal cell proliferation and local 
formation from androgen". Journal of Endocrinology 197 (3): 483–91. 
158 
   
31. Homma Y, Kawabe K, Tsukamoto T, et al. Estimate criteria for diagnosis and 
severity in benign prostatic hyperplasia. Int J Urol. 1996;3:261-266. 
32. Hutchison, A; Farmer, R; Verhamme, K; Berges, R; Navarrete, R (2007). "The 
Efficacy of Drugs for the Treatment of LUTS/BPH, A Study in 6 European 
Countries". European Urology 51 (1): 207–15 discussion 215–6. 
33. Jung K, Lein M, Butz H, Stephan C, Loening SA, Keller T. New insights into the 
diagnostic accuracy of complexed and total prostate specific antigen using 
discordance analysis characteristics. J Urol. 2006;175:1275-1280. 
34. K. Karthikeyan , P. Gunasekaran , N. Ramamurthy and S. Govindaswamy , 1999, 
35. Kaplan, S. A.; Roehrborn, C. G.; Rovner, E. S.; Carlsson, M.; Bavendam, T.; 
Guan, Z. (2006). "Tolterodine and Tamsulosin for Treatment of Men With Lower 
Urinary Tract Symptoms and Overactive Bladder: A Randomized Controlled 
Trial". JAMA: the Journal of the American Medical Association 296(19): 2319–
28. 
36. Kaplan, S; McConnell, J; Roehrborn, C; Meehan, A; Lee, M; Noble, W; Kusek, J; 
Nybergjr, L et al. (2006). "Combination Therapy With Doxazosin and Finasteride 
for Benign Prostatic Hyperplasia in Patients With Lower Urinary Tract Symptoms 
and a Baseline Total Prostate Volume of 25 Ml or Greater".The Journal of 
Urology 175 (1): 217–20; discussion 220–1.  
37. Lagiou, Pagona; Mantzoros, Christos S.; Tzonou, Anastasia; Signorello, Lisa B.; 
Lipworth, Loren; Trichopoubs, Dimitrios (1997). "Serum Steroids in Relation to 
Benign Prostatic Hyperplasia". Oncoogy 54 (6): 497–501. 
159 
   
38. Lieber, M M (1998). "Pharmacologic therapy for prostatism". Mayo Clinic 
Proceedings 73 (6): 590–6. 
39. Lipski BA, Garcia RL, Brawer MK. Prostatic intraepithelial neoplasia: 
significance and management. Semin Urol Oncol. 1996;14:149-155. 
40. MacDonald, Roderick; Wilt, Timothy J. (2005). "Alfuzosin for treatment of lower 
urinary tract symptoms compatible with benign prostatic hyperplasia: A 
systematic review of efficacy and adverse effects". Urology 66 (4): 780–8. 
41. MacDonald, Roderick; Wilt, Timothy J.; Howe, R. William (2004). "Doxazosin 
for treating lower urinary tract symptoms compatible with benign prostatic 
obstruction: a systematic review of efficacy and adverse effects". BJU 
International 94 (9): 1263–70. 
42. McVary, Kevin T.; Monnig, William; Camps Jr., Joseph L.; Young, Jay M.; 
Tseng, Li-Jung; Van Den Ende, Gene (2007). "Sildenafil Citrate Improves Erectile 
Function and Urinary Symptoms in Men With Erectile Dysfunction and Lower 
Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A 
Randomized, Double-Blind Trial". The Journal of Urology 177(3): 1071–7. 
43. Mycek J , Richard A , Harvey A , Pamela , Champe C ,2000, In: Anticancer drugs 
– Pharmacology , Lippincot- Raven Publication , Philadelphia , NY , P 373-378. 
44. Niu, YJ; Ma, TX; Zhang, J; Xu, Y; Han, RF; Sun, G (2003). "Androgen and 
prostatic stroma". Asian journal of andrology 5 (1): 19–26. 
45. Page, S. T.; Lin, D. W.; Mostaghel, E. A.; Hess, D. L.; True, L. D.; Amory, J. K.; 
Nelson, P. S.; Matsumoto, A. M. et al. (2006). "Persistent Intraprostatic Androgen 
160 
   
Concentrations after Medical Castration in Healthy Men". Journal of Clinical 
Endocrinology & Metabolism 91(10): 3850–6.  
46. Pearson JD, Luderer, Metter EJ, et al. Longitudinal analysis of serial 
measurements of free and total PSA among men with and without prostatic cancer. 
Urology. 1996;48(6A Suppl):4-9. 
47. Potts JM. The four categories of prostatitis: a practical approach to treatment. 
Cleve Clin J Med. 2001;68:389-90, 392-3, 397. 
48. Raminik sood, 1999, Medical Laboratory Technology. 5th edition ,P 404-414. 
49. Roberts, Rosebud O.; Jacobson, Debra J.; Rhodes, Thomas; Klee, George G.; 
Leiber, Michael M.; Jacobsen, Steven J. (2004). "Serum sex hormones and 
measures of benign prostatic hyperplasia". The Prostate 61(2): 124–31.  
50. Roehrborn, C; Boyle, P; Nickel, JC; Hoefner, K; Andriole, G; ARIA3001 
ARIA3002 and ARIA3003 Study Investigators (2002). "Efficacy and safety of a 
dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign 
prostatic hyperplasia". Urology60 (3): 434–41.  
51. Roehrborn, C; Bruskewitz, R; Nickel, J; McConnell, J; Saltzman, B; Gittelman, 
M; Malek, G; Gottesman, J et al. (2004). "Sustained Decrease in Incidence of 
Acute Urinary Retention and Surgery With Finasteride for 6 Years in Men With 
Benign Prostatic Hyperplasia". The Journal of Urology 171 (3): 1194–8. 
52. Roehrborn, CG (2008). "Current Medical Therapies for Men With Lower Urinary 
Tract Symptoms and Benign Prostatic Hyperplasia: Achievements and 
Limitations". Reviews in urology10 (1): 14–25.  
161 
   
53. Roehrborn, Claus G (2001). "Efficacy and safety of once-daily alfuzosin in the 
treatment of lower urinary tract symptoms and clinical benign prostatic 
hyperplasia: a randomized, placebo-controlled trial". Urology 58 (6): 953–9. 
54. Roehrborn, Claus G.; Nuckolls, James G.; Wei, John T.; Steers, William; BPH 
Registry and Patient Survey Steering Committee (2007). "The Benign Prostatic 
Hyperplasia Registry and Patient Survey: study design, methods and patient 
baseline characteristics".BJU International 100 (4): 813–9. 
55. Rubenstein, Jonathan; McVary, Kevin T. (6 February 2008). "Transurethral 
Microwave Thermotherapy of the Prostate (TUMT)". eMedicine. 
56. V Ramnath, Girija Kuttan and Ramadasan Kuttan, 2002, Anti tumour effect of 
Abrin on transplanted tumours in mice.Indian J Physiol.Pharmacol, Vol 46(1), P 
69-77. 
57. Verhamme, K; Dieleman, JP; Bleumink, GS; Van Der Lei, J; Sturkenboom, MC; 
Artibani, W; Begaud, B; Berges, R et al. (2002). "Incidence and Prevalence of 
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in 
Primary Care—The Triumph Project". European Urology42 (4): 323–8.  
58. Wasserman NF. Benign prostatic hyperplasia: a review and ultrasound 
classification. Radiol Clin North Am. 2006;44:689-710. 
59. Wasserman, Neil F. (1 September 2006). "Benign Prostatic Hyperplasia: A 
Review and Ultrasound Classification". Radiologic Clinics of North 
America 44 (5): 689–710. 
162 
   
60. Wei Wang, Qing-Long Guo, Qi-Dong You, Kun Zhang, Yong Yang, Jun Yu, Wei 
Liu , Li Zhao, Hong-Yan Gu , Yang Hu , Zi Tan and Xiao-Tang Wang, 2006,  The 
Anticancer activities of Wogonin In Murine sarcoma S180 both In Vitro and In 
Vivo. . J. Biol.Pharm.Bull. Vol.29(6), P 1132-1137. 
61. Wilt, Timothy J; Ishani, Areef; Rutks, Indulis; MacDonald, Roderick (2007). 
"Phytotherapy for benign prostatic hyperplasia". Public Health Nutrition 3(4A): 
459–72. 
62. Wilt, Timothy; Ishani, Areef; MacDonald, Roderick; Stark, Gerold; Mulrow, 
Cynthia D; Lau, Joseph; Wilt, Timothy (1999). Wilt, Timothy J. ed. "Beta-
sitosterols for benign prostatic hyperplasia". Cochrane Database of Systematic 
Reviews (2): CD001043. 
63. Wilt, Timothy; Ishani, Areef; Wilt, Timothy; Rutks, I; Stark, G (1998). Wilt, 
Timothy J. ed. "Pygeum africanum for benign prostatic hyperplasia". Cochrane 
Database of Systematic Reviews (1): CD001044. 
64. Wilt, Timothy; MacDonald, Roderick; Ishani, Areef; Rutks, Indy; Stark, Gerold; 
Wilt, Timothy (1998). Wilt, Timothy. ed. "Cernilton for benign prostatic 
hyperplasia". Cochrane Database of Systematic Reviews (2): CD001042. 
65. Wolf AM, Wender RC, Etzioni RB, et al. American cancer society guideline for 
the early detection of prostate cancer: update 2010. CA Cancer J Clin. 
2010;60(2):70-98. 
152 
 
Table-1: Effect of Velvanga Parpam treatment on the survival of tumour bearing mice 
Treatment MST (d) Life Span (%) 
Tumour control (Saline 3 ml/kg. p.o) 22 ± 0.572 - 
Velvanga Parpam (1.5mg/kg p.o) 26± 0.852** 15.38 
Velvanga Parpam (3mg/kg p.o) 34.32 ± 0.654** 35.89 
5-FU (20mg/kg i.p) 41.21 ± 0.442** 46.61 
**P<0.01 Vs Tumour control; Data were analyzed by one way ANOVA followed by dunnet test. N = 6 
Table-2: Effect of Velvanga Parpam on solid tumor volume 
Treatment Dose (mg/kg) 
Solid tumor volume (ml) 
15th Day 20th day 25th day 30th day 
Tumor control - 3.60 ± 0.131 4.10 ± 0.090 5.44 ± 0.210 6.63 ± 0.131 
Velvanga Parpam  (1.5 p.o) 2.10 ± 0.052** 3.11 ± 0.062** 3.53 ± 0.091** 4.15±0.094** 
Velvanga Parpam  (3 p.o) 1.79 ± 0.044** 2.42 ± 0.054** 3.14 ± 0.066** 3.42± 0.082** 
5-FU  (20 i.p) 2.05 ± 0.035** 2.28 ± 0.035** 2.22 ± 0.052** 3.21 ± 0.060** 
**P<0.01 Vs Tumour control; Data were analyzed by one way ANOVA followed by dunnet test. N = 6 
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Table-3: Effect of Velvanga Parpam treatment on the heamatological profile of tumour bearing mice 
 
**P<0.01 Vs Tumour control; Data were analyzed by one way ANOVA followed by dunnet test. N = 6 
 
 
 
 
 
Treatment Hb (g%) Differential count % RBC 
(million/mm3) 
WBC 
(103cells/mm3) 
Proteins 
(g%) 
PCV 
(mm) Lymphocyte Neutrophil Monocyte 
Normal saline 
(5 ml/kg) 
14.2±0.4** 68.1±1.2** 26.5±1.4** 3.1±0.5 6.8±0.6** 7.5±0.5** 8.2±0.4** 16.8±0.5** 
DAL control 
(1 x 106 cell) 
7.4±0.5 32.2±0.2 65.2±1.6 3.5±0.4 3.5±0.2 14.6±1.0 13.1±1.2 24.5±0.3  
DAL (1 x 106 cell) + 
VP (1.5mg/kg p.o) 
10.8±0.4** 
 
52.4±1.4** 40.4±1.5** 2.7±0.6 5.2±0.5* 10.5±0.5** 10.1±0.4** 19.8±0.5** 
DAL (1 x 106 cell) + 
VP (3mg/kg p.o) 
12.1±0.5** 68.2±2.3** 31.6±2.5** 3.1±0.4 
 
5.2±0.3* 8.0±0.4** 9.0±0.2** 18.6±0.2** 
DAL (1 x 106 cell) + 
5FU (20 mg/kg i.p) 
12.0±0.5** 66.0±2.0** 32.4±2.4** 2.9±0.4 5.4±0.2** 7.2±0.6** 8.4±0.3** 17.2±0.3** 
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PHARMOCOLOGICAL STUDY OF VELVANGA PARPAM 
HISTOPATHOLOGY 
CONTROL: 
 
 
 
 
 
STANDARD: 
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1.5 mg: 
 
      
 
 
 
3 mg: 
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BIOSTATISTICAL ANALYSIS 
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ANNEXURE- IV 
BIOSTATISTICAL ANALYSIS 
Effect of Velvanga Parpam on IPSS in human subjects 
S.No IPSS 
Before Treatment After Treatment 
1 7 5 
2 19 12 
3 32 28 
4 18 10 
5 17 7 
6 17 12 
7 15 7 
8 11 6 
9 19 13 
10 14 7 
11 13 6 
12 7 4 
13 28 12 
14 24 16 
15 16 9 
16 16 8 
17 13 8 
18 10 5 
19 27 24 
20 14 7 
 
Software: spss17 version 
Variables: IPSS – before treatment, after treatment 
Number of cases: 20 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.893 
Before and after treatment mean difference: -6.55±3.02 
P Value (2 tailed): p<0.01. 
Inference: The p value is significant (p<0.01).  So the treatment was significantly 
reduces the symptoms score (IPSS). 
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Consent Form 
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ANNEXURE-V 
CONSENT FORM 
 
        I certify that I have disclosed all the details about the study in the terms readily 
understood by the patient. 
 
Date   :                                                                                          Signature                                                                                                                            
Name   : 
 
Consent By The Patient 
 
        I have been informed to my satisfaction by the attending physician for the purpose 
of the clinical trial and the nature of the drug treatment and follow up including the lab 
investigation to be performed to monitor and safeguard my body functions. 
        I am aware of my right to opd out of the trial at any time during the course of the 
trial without having to give reasons for doing so. 
         I, exercising my free power of choice, hereby give my consent to be included as a 
subject in the clinical trial of VELVANGA PARPAM for the treatment of UKKARA 
SOOLAI. 
 
 
Name :         Signature 
Date : 
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§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø ÀÊÅõ 
 
 
           ¾¢Õ. ___________________________¬¸¢Â ¿¡ý ___________ÅÂÐ,         
(___________________________________________________________
___________________________________________________________  
Åº¢ìÌõ þ¼õ.) ±ý ÍÂ ¿¢¨É×¼ý ±Ø¾¢ì ¦¸¡ÎìÌõ ´ôÒ¾ø ÀÊÅõ. 
 
          ¿¡ý ÒÃŠò¾ §¸¡Ç Å£ì¸õ (¯ì¸¡Ã Ý¨Ä) ±ýÛõ §¿¡Â¡ø À¡¾¢ì¸ôÀðÎ 
¦ºý¨É,«ÃÍ º¢ò¾ ÁÕòÐÅ ¸øæ¡¢Â¢ø (þ¼õ: «È¢ï÷ «ñ½¡ þó¾¢Â 
ÁÕòÐÅÁ¨É, «ÕõÀ¡ì¸õ, ¦ºý¨É-106.) ¿¼ò¾ôÀÎõ º¢ò¾ ÁÕòÐÅ 
¬Ã¡öîº¢ ãÄõ º¢¸¢î¨º ¦ÀÈ ±ý ÍÂ ¿¢¨É×¼ý ÓØºõÁ¾ò¨¾Ôõ 
¦¾¡¢Å¢òÐì¦¸¡û¸¢§Èý. 
 
          þó¾ ¬Ã¡öîº¢Â¢ý §¿¡ì¸õ, ÁÕòÐÅõ ¦ºöÔõ Ó¨È, ¦¾¡¼÷¸ñ¸¡½¢ôÒ 
ÁüÚõ ±ý ¯¼ø ¿Äõ ÌÈ¢ò¾ ÁÕòÐÅ À¡¢§º¡¾¨É¸¨Çô ÀüÈ¢Â Å¢¡¢Å¡É 
Å¢Çì¸õ ±ÉìÌ ÁÕòÐÅõ ¦ºöÔõ ÁÕòÐÅ÷ ãÄõ ¦¾Ç¢×ÀÎò¾ôÀðÎûÇÐ. 
þó¾ ¬Ã¡öîº¢Â¢ø ÀíÌ¦¸¡ûÙõ ±ý ºõÁ¾ò¾¢üÌ Â¡Õ¨¼Â ¿¢÷Àó¾Óõ 
¸¡Ã½Á¢ø¨Ä±ýÀ¨¾ ¦¾¡¢Å¢òÐì¦¸¡û¸¢§Èý. 
 
 
þôÀÊìÌ, 
 
 
 
 
 
¦ÀÂ÷     : 
Ó¸Å¡¢  : 
 
¿¡û      : 
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Case sheet proforma 
 
 
 
 
 
 
 
 
 
 
 
 
 
171 
   
ANNEXURE- VI 
CASE SHEET  
POST GRADUATE DEPARTMENT - BRANCH-I 
 (POTHU) MARUTHUVAM  
GOVT. SIDDHA MEDICAL COLLEGE & ANNA HOSPITAL, CHENNAI-106. 
CASE SHEET PROFORMA FOR “UKKARA SOOLAI” 
WARD NO. : NATIONALITY : 
I.P. NO : RELIGION : 
BED NO : OCCUPATION : 
NAME : INCOME : 
AGE : D.O.A : 
SEX : D.OD                            : 
PERMANENT ADDRESS :  
  DIAGNOSIS : 
 
TEMPORARY ADDRESS:  
Govt. Siddha Medical College & 
Anna Hospital, Chennai – 106.                            MEDICAL OFFICER : 
 
 
 
COMPLAINTS AND DURATION : 
 
 
 
 
 
HISTORY OF PRESENT ILLNESS: 
 
 
 
 
HISTORY OF PAST ILLNESS : 
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PERSONAL HISTORY & HABITS : 
1. Diet          : Veg.   Non veg.    
2. Marital status    :   single        married 
3. Emotional stress  : Yes          No 
4. Addiction    : Yes    No 
• If yes specify :_____________________________________________ 
5. Bowel habit    :     Regular        Constipation 
6. Sleep     :         Good                  Disturbed              Insomnia 
7. Presence of anxiety   : Yes   No 
 
FAMILY HISTORY: 
• Cardiovascular disease  Yes  No 
• Tuberculosis   Yes  No 
• Others   Yes  No 
 
If yes specify :                                                                                 . 
 
GENERAL EXAMINATION: 
1. Physical build :     lean                normal                   obese  
2. Height (cm) : 
3. Weight(kg)  : : 
4. Pulse rate  : 
5. Heart rate : 
6. Respiratory rate : 
7. Blood pressure  : 
8.  Pallor   : 
9. Cyanosis  : 
10. Jaundice : 
11. Clubbing  : 
12. Pedal oedema : 
13. JVP :  
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SYSTEMIC EXAMINATION: 
• CVS   :                 Normal                              Abnormal 
o If abnormal , details_______________________________________ 
• CNS  :                  Normal                            Abnormal 
o If abnormal , details_______________________________________ 
• Respiratory system     :          Normal                             Abnormal 
o If abnormal , details_______________________________________ 
• Digestive system :                Normal                            Abnormal 
o If abnormal , details_______________________________________ 
• Urogenital  system :                Normal                            Abnormal 
o If abnormal , details_______________________________________ 
SIDDHA ASPECTS 
Yaakai (udal nilai)      Mukkunam  
1. Vatham        1. Sathuva gunam 
2. Pitham       2. Raasatha gunam  
3. Kapham       3. Thamo gunam 
4. Kalappu 
PARUVA KAALAM (SEASONS)   
1. Kaar Kaalam (Aavani-Puratasi) Aug-sept.    
2. Koothir Kaalam (Iypasi-Karthigai) Oct-Nov.  
3. Munpani  Kaalam (Maargazhi-Thai) Dec-Jan 
4. Elavenil Kaalam (Chithirai-Vaikasi) Apr-May  
5. Mudhuvenil  Kaalam (Aani-Aadi) Jun-Jul 
 
NILAM (PLACES)  
                1.Kurinchi (Hills  Areas) 
 2.Mullai (Forest Areas) 
 3.Marudham (Fertile Areas) 
 4.Neithal (Sea Areas) 
 5.Paalai (Desert Areas) 
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IYAMPORIGAL/PULANGAL  
  
1. Mei  (Sensation)  : 
2. Vaai (Taste)  : 
3. Kann  (Vision)  : 
4. Mooku(Smell)  : 
5. Sevi (Hearing) : 
 
KANMENTHIRIYAM / KANMAVIDAYAM 
 
 1.Kai [Koduthal] : 
 2.Kaal [Nadathal] : 
 3.Vaai [Pesal] : 
 4.Eruvai [Malam Kazhithal] :  
 5.Karuvai [Aananthithal] : 
MUMMALAM 
1. Malam 
2. Moothiram 
3. Viyaravai 
 
UYIR THATHUKKAL: 
 Vatham: 
1. Pranan :  6.  Naagan: 
2. Abanan :  7.  Koorman: 
3. Viyanan :  8.  Kirukaran: 
4. Udhanan :  9.  Devadathan: 
5. Samanan:  10. Dhananjeyan: 
PITHAM:   KAPHAM: 
1. Anal Pitham:  1.  Avalambagam: 
2. Ranjaga Pitham:   2.  Kledagam: 
3. Saadhaga Pitham:   3.  Podhagam: 
4. Aalosaga Pitham :  4.  Tharpagam: 
1. Prasaga Pitham:  5.  Santhigam: 
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UDAL THATHUKKAL: 
1. Saaram : 
2. Senneer :  
3. Oon : 
4. Kozhuppu : 
5. Enbu : 
6. Moolai : 
7. Sukkilam / Suronitham: 
ENVAGAI THERVU: 
1. Naa -  
2. Niram              - 
3. Mozhi -  
4. Vizhi -  
5. Sparisam         - 
6. Malam  
a. Niram 
b. Nurai 
c. Erugal   
d. Elagal 
7. Moothiram 
a.  Neerkuri  
1.  Niram 
2. Edai 
3. Manam 
4. Nurai 
5.  Enjal 
b. Neikuri 
8. Naadi 
  
Neikuri examination: 
             Before treatment:  After treatment: 
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SIGNS AND SYMPTOMS   : 
          
 
Date Day Wt BP Clinical Data IPSS Sign of M.O 
 0    
 
 
  
 1st visit 
15th Day 
   
 
 
  
 2nd visit 
30th Day 
   
 
 
  
 3rd visit 
45th Day 
   
 
 
  
 1st 
Follow 
up visit 
   
 
 
  
 2n 
Follow 
up visit 
     
 
LABORTORY INVESTIGATIONS: 
 
Blood: 
 
S.No Parameters Before 
 treatment 
After treatment 
1. USG – KUB 
 
  
2. Post void residual urine   
3. PSA Test   
4. TC   
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5. DC   
6. Hb gms%   
7. ESR  30 mints 
          60 mints 
  
8. Blood Sugar  (F) 
                        (P) 
  
9. S.Cholesterol   
10. B.Urea   
11. B.Creatinine   
          
 
                            
Urine: 
 
s.no. Parameters Before treatment After treatment 
1. Albumin   
2. Sugar   
3. Deposits   
 
 
 
TRAIL DRUG       :    VELVANGA PARPAM 
Dose                        :   65 mg 
Anubanam             :    Honey / butter 
Duration of treatment:  45 days 
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Pathiam (Do’s and Don’ts) 
 
 
 
Prognosis at the end of the treatment 
 
 
 
 
 
 
 
 
Medical Officer Signature:  PROF. / H.O.D 
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